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ABSTRACT 
Neurodegenerative diseases (NDs) include a broad range of age-related neuropathological 
conditions characterized by a slow but unstoppable highly selective degenerative process. It 
involves distinct subsets of neurons in specific anatomic systems leading to variable disease 
phenotypes such as cognitive impairment, movement disorders or a combination of both. 
However, the gradual accumulation of misfolded protein aggregates in well-ordered structures, 
habitually called amyloid represent a common feature of NDs and is thought to be at the root of 
these diseases. Some of these proteins are prion protein, beta amyloid, tau, TDP43 and alpha 
synuclein on which we focused our attention. Alpha-synuclein(α-syn) is a 140 amino acid 
protein widely expressed in the brain occurring as a soluble or membrane-associated protein at 
presynaptic nerve terminals. It is mainly involved in synaptic vesicle release and trafficking. In 
its membrane-bound protein form, α-syn has a predominantly α-helical structure which under 
certain conditions can alternatively fold into a β-sheet-rich structure that easily polymerizes into 
amyloid fibrils and aggregates. These aggregates acquire neurotoxicity affecting mitochondrial 
function, endoplasmic reticulum–Golgi trafficking, protein degradation and/or synaptic 
transmission, leading to neurodegeneration. Interestingly, aggregated forms of α-syn can recruit 
and seed the endogenous protein and initiate the spreading throughout cells, thus suggesting a 
prion-like mechanism. The occurrence of Lewy bodies/Lewy neurites containing misfolded 
fibrillar α-syn constitutes one of the pathological hallmarks of synucleinopathies such as 
Parkinson’s disease, dementia with Lewy Bodies and multiple system atrophy, all linked to 
memory impairments. While it has been shown that brainstem Lewy bodies may contribute to 
motor symptoms, the anatomical and neuropathological substrates for cognitive symptoms are 
still elusive. Therefore, in this PhD thesis I sought to investigate the progressive pathologic 
alterations and spreading of synthetic α-syn fibrils bilaterally injected into the hippocampus of 
adult female Sprague-Dawley rats, up to the onset of memory impairments. Animals underwent 
behavioral testing for sensory-motor and spatial learning and memory abilities at different time-
points post-injection. At no time-point was any sensory-motor deficits observed that could affect 
performance in the Morris Water Maze task, nor was any reference memory disturbances 
detected in any of the injected animals. By contrast, significant impairments in working memory 
performance became evident at 12 months post-injection. These deficits were associated to a 
time-dependent increase in the levels of phosphorylated α-syn at serine 129 and in the 
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stereologically-estimated numbers of proteinase K-resistant α-syn aggregates within the 
hippocampus. Interestingly, pathological α-syn aggregates were found in the entorhinal cortex 
and, by 12 months post-injection, also in the vertical limb of the diagonal band and the piriform 
cortices, all anatomically related to the injected sites. No pathological α-syn deposits were found 
within the Substantia Nigra, the Ventral Tegmental Area or the Striatum, nor was any obvious 
loss of dopaminergic, noradrenergic or cholinergic neurons detected in α-syn injected animals, 
compared to controls. This would suggest that the behavioral impairments seen in the α-syn 
injected animals might be determined by the long-term persisting α-syn neuropathology in the 
affected neurons rather than by neurodegeneration per se. 
This study confirms and extends previous observations showing that hippocampal α-syn 
pathology contribute to specific memory impairment. In addition, the α-syn preformed fibrils 
infusion procedure in the rat may represent a feasible tool to model synucleinopathies with which 
to test possible therapeutic interventions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
                                                                                                                                  CHAPTER I 
 
 
INTRODUCTION 
 
I Neurodegenerative diseases 
 
Parkinson's disease (PD) together with Alzheimer’s (AD), Amyotrophic Lateral Sclerosis (ALS), 
Huntington's disease (HD), Frontotemporal dementia (FTD), Dementia with Lewy bodies 
(DLB), belong to neurodegenerative diseases which enclose a broad range of age-related 
neuropathological conditions characterized by a slow but unstoppable highly selective 
degenerative process. It involves distinct subsets of neurons in specific anatomic systems leading 
to variable disease phenotypes such as cognitive impairment, movement disorders or a 
combination of both [1]. Another common feature of NDs is the accumulation in the human 
brain and peripheral organs of disease-specific proteins with altered physicochemical properties 
hence the name of conformational Diseases [2]. Comparatively, the disorders appear at the dawn 
of old age with a long clinical course followed by a complete disability which has a major 
negative impact at the professional, social and economic level on the lives of patients. Thus, NDs 
have become a tremendous burden for both families and society. They are almost 50 million 
affected worldwide and this number is expected to rise up substantially due to increasing life 
expectancy[3]. Despite the amount of work that has been carried out to develop disease-
modifying treatments, none of them is able to stop the progression of the diseases, making NDs 
incurable until today. 
 
1. Classification 
 
The classification of NDs is based on the clinical presentation, anatomical regions and cell types 
affected, conformationally altered proteins involved in the pathogenetic process, and etiology if 
known (i.e., genetic variations or acquired pathways, for example, in prion diseases)[4]. Thus, 
the classification can be done following two different approaches subdivided in two groups:  
 
The clinical classification  
  
It is determined by the anatomical regions showing neuronal dysfunction or loss and allow 
focusing on early symptoms considering that in most NDs, there is an overlapping of clinical 
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symptoms, which occurs during the clinical course. Thus, involvement of the hippocampus, 
entorhinal cortex, limbic system, and neocortical areas can lead to clinical manifestations like 
cognitive decline, dementia and alterations in high-order brain functions. While, Movement 
disorders including hyperkinetic and hypokinetic disorders, are linked to the involvement of the 
basal ganglia, thalamus, brainstem nuclei, cerebellar cortex and nuclei, motor cortical areas, and 
lower motor neurons of the spinal cord[5][5]. In frontotemporal dementia, a subset of dementia, 
the neural degeneration mainly affects the frontal and temporal lobes (frontotemporal lobar 
degeneration, FTLD)[4].  
 
The molecular pathological classification 
 
 
The molecular pathological classification focuses on the distinction of synaptic, intracellular, 
extracellular protein accumulations and the subcellular location of the intracellular deposits (e.g., 
nuclear, cytoplasmic or cell process)[6]. With the development new antibodies, 
immunohistochemistry is mainly used for subtyping diseases, which describe novel 
immunostaining patterns whether biochemistry and genetic analysis are often required as a 
complementary examination to immunohistochemistry. However, there are some forms of NDs, 
like hereditary spastic paraplegia or some variants of spinocerebellar ataxia, where no specific 
protein inclusions are detected with currently available methods. According to the proteins 
associated with the majority of sporadic and genetic adult-onset NDs we can distinguish: 
 
• Prion diseases 
 
Prion diseases are a group of pathological conditions affecting both humans and animals and 
characterized by the aggregation within the brain of misfolded form of the cellular prion protein 
(PrPC), called scrapie prion protein (PrPSc) or prion (PrP) [7, 8] which leads to brain damage. The 
classification of prion diseases is based firstly on the etiology as idiopathic/sporadic, acquired 
and genetic forms. Clinicopathological phenotypes include Creutzfeldt-Jakob disease (CJD: 
spongiform encephalopathy; sporadic, iatrogenic, variant or genetic), kuru, Gerstmann-
Sträussler-Scheinker disease (PrP-amyloidosis), and familial or sporadic fatal insomnia (selective 
thalamic degeneration without prominent spongiform change) [9]. Secondly, it is based on 
immunostaining for disease-associated PrP, biochemical examination the size of the Proteinase K 
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(PK)-resistant core of PrPSc (i.e., type 1migrating at 21 kDa and type 2 at 19 kDa), and 
examination of the PrP gene (PRNP) (mutations and the genotype at the polymorphic codon 129; 
methionine, M, or valine, V) [9]. The combination of these molecular features distinguishes the 
bovine spongiform encephalopathy-related acquired form variant CJD, iatrogenic CJD, the 
recently described disorder termed variably protease-sensitive prionopathy (VPSPr), and certain 
genetic forms of disease. Morphologically, Major disease-associated PrP deposits comprise 
diffuse/synaptic, fine or coarse perineuronal immunopositivity, patchy/perivacuolar, plaque-like 
(lacking amyloid characteristics, thus called PrP plaques), and amyloid plaques. However, it is 
must be mentioned that florid plaque-like structures, which are amyloid plaques surrounded by a 
collar of vacuoles and additional PrP immunoreactivities such as multiple small cluster plaques, 
amorphous and star-like pericellular and perivascular PrP deposits [10] represent a characteristic 
sign of variant CJD, although already described in iatrogenic CJD [11].   
 
• Alzheimer disease 
 
The extracellular deposition of Amyloid β (Aβ) fibrils and the intraneuronal accumulation of 
abnormally phosphorylated tau protein represent the pathological hallmarks of AD. The 
accumulation of Aβ fibrils can occur in the parenchyma in the form of plaques and in the vessel 
walls as cerebral amyloid angiopathy (CAA). Parenchymal Aβ deposits display different 
morphologies, like stellate (probably related to astrocytes), diffuse deposits (further divided into 
fleecy, lake-like or subpial) or focal deposits (such as those with or without a dense core), and 
further rare morphologies like cotton-wool plaques [12]. Following the stereotypical pattern of 
protein pathology in AD, Braak and coworkers proposed either a staging scheme for 
neurofibrillary (tau) pathology or phases for Aβ deposition[13, 14]. Regarding tau pathology, 
strategic areas include the transentorhinal cortex (stage I), entorhinal cortex (stage II), inferior 
(stage III) and middle temporal gyri (stage IV), while for the end stages an examination of the 
occipital cortex is needed (peristriate for stage V and striate cortex for stage VI) [13]. 
Furthermore, it has been shown that subcortical nuclei also display early tau pathology and is 
indicated as early subcortical stages a, b, c [15], or as early pre-cortical evolutional phase [16]. 
Regarding Aβ deposition, five phases were proposed following the progressive involvement of 
isocortical areas (phase 1), hippocampus and entorhinal cortex (phase 2), basal ganglia and 
diencephalon (phase 3), brainstem (phase 4) and cerebellum (phase 5). Recently, the Braak 
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stages and Thal phases, together with the classical semiquantitative scoring of neuritic plaques 
[17], have been inserted in the NIA-AA neuropathological criteria for AD [18]. 
 
• Tauopathies 
 
Tauopathies account for a heterogeneous group of disorders characterized by pathological 
intracellular deposits of the protein tau. Taupathies can be subdivided in two main groups: the 
primary tauopathies when tau pathology is the driving force in the pathogenesis or secondary 
tauopathies. when tau pathology is not the driving force. Primary tauopathies are grouped based 
on the ratio of 3 repeat (R)-tau and 4R-tau isoforms and two or three major bands (60, 64 and 68 
kDa) in western blot of sarkosyl-insoluble fractions. Further classification is related to the 
distinct involvement of anatomical areas and cell types, and ultrastructural features of tau 
filaments [4]. The 3R tauopathy Pick’s disease is characterized by neuronal spherical Pick 
bodies, ramified astrocytes and less frequently, small oligodendroglial globular inclusions[19]. 
4R tauopathies comprise progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD), globular glial tauopathies (GGT) and argyrophilic grain disease (AGD). Comparably less 
neuronal inclusions comprising 4R immunoreactive spherical inclusions, globular Neurofibrillat 
tangles (NFT) NFT-like structures and diffuse cytoplasmic tau immunoreactivity are seen. The 
mixed 3R and 4R tauopathy affecting the medial temporal lobe, termed also as NFT-predominant 
dementia, represents the severe end of primary age-related tauopathy (PART) [20]. Secondary 
tauopathies include AD, in which deposit of Aβ plaques is associated with tau pathology and 
chronic traumatic encephalopathy (CTE), in which tau pathology is thought to be induced by 
repeated mild head injuries [21]. 
 
• Αlpha-synucleinopathies 
 
Αlpha-synucleinopathies are a group of diseases characterized by the abnormal accumulation of 
aggregates of α-syn protein in neurons, nerve fibers or glial cells, α-synucleinopathies are 
subdivided in two main groups: the neuron and glia predominant α-synucleinopathies [6]. The 
neuron-predominant α-synucleinopathies display Lewy body (LB) pathology and are further 
classified according to the earliest nature of symptoms (movement disorder or cognitive decline) 
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including DLB, PD, and PD with dementia (PPD). We can have also incidental Lewy bodies’ 
diseases where Lewy bodies are potentially detected despite the lack of clinical symptoms. One 
of the neuropathological approaches for Lewy body pathology classification concern the staging 
of α-syn pathology according to Braak and colleagues. This includes the sequential involvement 
of the medulla oblongata (stage 1), pons (2) mesencephalon (3; e.g., the substantia nigra), limbic 
areas (4) and neocortical areas (5 and 6),   [22]. However, the existence of cases, which do not 
strictly follow these stages, outlined the presence of disease forms with Lewy bodies where α-
synuclein pathology is generated ‘spontaneously’ in a specific region, [22]. Another approach 
proposed by Kosaka et al is applied in the diagnostic criteria for DLB (ie, brainstem, limbic and 
neocortical types)[23]. Further suggestions for classification have emerged due to the subsistence 
of disease forms where Lewy bodies are restricted to the amygdala, [24, 25] while the olfactory 
bulb is known to be the earliest affected. The unified staging system for Lewy body disorders 
classifies Lewy body disorders as olfactory bulb only, brainstem-predominant, limbic-
predominant, brainstem and limbic and neocortical [26]. Regarding the glia predominant α-
synucleinopathies, represented mainly by multiple system atrophy (MSA), the simple presence 
of oligodendroglial inclusions (Papp-Lantos bodies) is enough for the diagnosis [27]. Based on 
the distribution of glial inclusions which can follow a striatonigral or olivopontocerebellar 
predominance, clinical subtypes such as MSA-P (Parkinsonism dominant) and MSA-C 
(cerebellar symptom-predominant) are defined. Nevertheless, these cannot be clearly translated 
into biochemical or morphological differences [28]. Recently, a further type has been described 
with FTLD [29]. Furthermore, α-syn immunoreactive deposits can be observed in the ependyma, 
perivascular cells, cranial nerves, retina, gastrointestinal tract, peripheral organs and skin [30]. 
 
• TDP-43 proteinopathies 
 
Inclusions of pathogenic deposits containing TAR DNA-binding protein 43 (TDP-43) are one of 
common pathological hallmarks of amyotrophic lateral sclerosis (ALS) and a common[31] form 
of FTLD. Markedly, up to 40% of cases are linked to multiple gene mutations including C9orf72 
(most frequent), granulin (GRN), valosin-containing protein (VCP), TARDBP (the gene 
encoding TDP-43) etc. [32, 33]. TDP-43 immunoreactive deposits can be found in the 
cytoplasm, nucleus, and neurites of neurons. Furthermore, skein-like and spherical inclusions are 
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described in ALS[34].  According to a harmonized classification system we distinguish four 
subtypes (A–D), based on the predominance and layer, predominance of neuritic and neuronal 
cytoplasmic, or intranuclear inclusions. Interestingly, these patterns can also predict the genes 
involved in hereditary forms [35]. Finally, a further type (E) has been described in rapidly 
progressive forms (duration <3 years) [36]; this awaits further confirmation from larger cohorts. 
TDP-43 pathology frequently associates with other disorders like AD, DLB, hippocampal 
sclerosis and chronic traumatic encephalopathy. Some of these associations are related to genetic 
or other risk factors [37, 38]. The cellular distribution of TDP-43 pathology can be similar to the 
FTLD-TDP one, with only rare neuronal nuclear inclusions and variable presence of glial 
deposits. Recently an entity termed limbic-predominant age-related TDP-43 encephalopathy 
(LATE) has been defined. LATE allows the recognition of a stereotypical medial temporal lobe-
predominant TDP-43 proteinopathy in older adults, with or without coexisting hippocampal 
sclerosis pathology that is associated with an amnestic dementia syndrome mimicking AD-type 
dementia. While LATE-NC described the neuropathological changes[39]  
 
• FET/FUS proteinopathies 
 
Conditions characterized by intra-nuclear and intra-cytoplasmatic deposition of RNA-binding 
proteins belonging to the FET (FUS/TLS, EWS or TAF15) family. Rare sporadic disorders 
associated with FTLD, such as basophilic inclusion body disease, atypical FTLD-U and neuronal 
intermediate filament inclusion disease, show neuronal (cytoplasmic/ nuclear) and glial 
cytoplasmic inclusions immunoreactive for FET proteins [40, 41]. The inclusion types and their 
regional distribution in FTLD distinguish these forms in most cases. In contrast, FUS gene 
mutation-related ALS cases are only immunoreactive for FUS and not for further FET proteins 
[40]. 
 
• Rare disease forms 
 
They group different types of disorders of which some of the most relevant are represented by a 
group of diseases such as hereditary ataxia and Huntington's disease that are associated with the 
expansion of unstable trinucleotide repeats in some genes that lead to the aggregation of genic 
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products [42]. Another group of disorders are neuroserpinopathies that result from point 
mutations in the Neuroserpin gene, a member of the serpin family of serine protease inhibitors, 
promoting the formation of neuroserpin-compound inclusion bodies in the brain [43]. Ferritin-
related NDs are characterized by a genetic defect in the ferritin light polypeptide gene that leads 
to the accumulation of ferritin deposits in the brain and peripheral organs [44]. Furthermore, 
there are hereditary brain amyloidosis, where deposited proteins include Aβ, transthyretin, 
gelsolin, cystatin, PrP and BRI2 proteins. Finally, there are diseases for which specific inclusions 
have not been described (eg, FTLD-ni; no inclusions) [45]. A summary of the most relevant 
neurodegenerative disease is shown in the Table below: 
 
 
Disease group 
 
Protein Disease types Form Phenotype 
Prion diseases  
 
PrP sCJD, VPSPr, sFI 
iCJD, vCJD, Kuru 
gCJD, GSS, FFI, PrP-CAA 
SP 
ACQ 
GEN 
DEM/MD 
DEM/MD 
DEM/MD 
Alzheimer disease Aβ, Tau Alzheimer disease SP/GEN DEM 
Taupathies 
FTLD-Tau 
Tau Pick disease, GGT 
CBD, PSP 
AGD, NFT-dementia/PART 
FTDP-17T 
SP 
SP 
SP 
GEN 
FTD 
MD/FTD 
DEM 
FTD/MD 
αsynucleinopathies α-synuclein Parkinson disease 
Dementia with Lewy body 
multiple sytem atrophy 
SP/GEN 
SP/DEM 
SP 
MD 
DEM/MD 
MD 
TDP-43 
proteinopathies 
TDP43 FTLD-TDP(Type A-D) 
MND-TDP 
FTDL-MND-TDP 
SP/GEN 
SP/GEN 
SP/GEN 
FTP 
MD 
FTD-MD 
FUS/FET-
proteinopathies 
FUS/FET aFTLD-U, NIFID, BIBD 
MND-FUS 
SP 
GEN 
FTD/MD 
MD 
Trinucleotide 
repeat expansion 
disorders (TRD) 
Huntington 
Ataxin1,2,37, 
CACNA1A,TBP 
FMRP 
ARP 
Huntington disease 
Spinocerebellar ataxia (SCA) 
1,2,3,6,7,17 
FXTAS 
SBMA 
GEN 
GEN 
 
GEN 
GEN 
MD 
MD 
 
MD 
MD 
Neuroserpinopathy Neuroserpin Neuroserpinopathy GEN DEM 
Neuroferritinopathy Ferritin Hereditary ferritinopathy GEN DEM/MD 
Hereditary 
amyloidosis 
ABri, Adan, 
Gelsolin, Cystatin, 
Transthyretin, Aβ 
Hereditary amyloidosis/CAA GEN DEM 
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Table 1. Summary of the most relevant neurodegenerative diseases classified 
according to their protein deposits. Abbreviations: ACQ: acquired; ARP: androgen 
receptor protein;  AGD: Argyrophilic grain disease; BIBD: Basophilic inclusion body 
disease; CAA: sporadic cerebral amyloid angiopathy;CACNA1A:1A subunit of the P/Q-
type voltage-gated calcium channel (SCA6; Cytoplasmic aggregates); CBD: Corticobasal 
degeneration; CJD: Creutzfeldt-Jakob disease (i: iatrogenic, s: sporadic, v: variant, g: 
genetic); DEM: dementia; sFI: sporadic fatal insomnia; FFI: fatal familial insomnia; 
FMRP: Fragile X mental retardation protein; FTD: frontotemporal dementia; 
FTLD:frontotemporal lobar degeneration; aFTLD-U: atypical FTLD with ubiquitinat: 
FTLD-ni: FTLD no inclusion specified; FTDP-17T: Frontotemporal dementia and 
parkinsonism linked to chromosome 17 caused by mutations in the MAPT (tau) gene; 
FXTAS: Fragile X associated tremor and ataxia syndrome (here also astroglial 
inclusions); GEN: genetic; GGT: globular glial tauopathy; GSS: Gerstmann-Sträussler-
Scheinker disease; INIBD: intranuclear inclusion body diseases; MD: movement 
disorder; MND: Motor neuron disease;  NIFID: Neurofilament intermediate filament 
inclusion disease; PrP: prion protein; PSP: Progressive supranuclear palsy; SCA: 
spinocerebellar ataxia; SBMA: spinal and bulbarmuscular atrophy; SP: sporadic; TBP: 
TATA-Box binding protein (SCA17); VPSPr: variably protease-sensitiveprionopathy. [6] 
 
2. Etiology and pathogenesis  
 
            Aging, genetic, and environmental factors 
 
Generally, neurodegenerative diseases are multifactorial in origin although aging and 
genetic factors remain greatest risk factors. Indeed, peculiar hallmarks of aging like 
genomic instability, telomere attrition, epigenetic alterations, and loss of proteostasis, 
mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, stem cell 
depletion and altered intercellular communication correspond with susceptibility to 
neurodegenerative disease [46]. Moreover, DNA damage, mitochondrial dysfunction, 
cellular senescence and inflammation, which are often thought to lead to 
neurodegeneration, show great interconnection with the others ageing-related hallmarks. 
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For instance, defects in DNA repair contribute to genomic instability, which increases 
with age [47]. It has been shown that the proteostasis decline, consequent to dysfunctions 
in proteasome or autophagy observed in AD and PD, is highly linked to inflammation 
[48]. There is also a correlation between metabolic dysfunction observed in 
neurodegeneration and alterations in NAD+ levels, mitochondrial dysfunction and 
oxidative stress [49]. Furthermore, the Loss of functional stem cells is linked to most of 
the ageing hallmarks, including DNA damage, epigenetic deregulation, mitochondrial 
dysfunction, telomerase inactivation and cell senescence [50]. 
Beside contributing to the aging process, genetic factors have a crucial role in the 
development of neurodegenerative diseases which majority are sporadic in occurrence 
with 5-10% familial. Familial forms of neurodegenerative diseases show a strong genetic 
component and the identification of mutations that cause disease in some genes such as 
amyloid precursor protein gene (APP) for AD, alpha synuclein gene (SNCA) in PD and 
tau in FTD have provided insights into their pathogenesis. Regarding sporadic forms, 
they are presumably owing to the involvement of different genes of susceptibility to 
multiple loci and interaction between them and / or environmental factors [51]. In fact, 
the ε4 allele of the apolipoprotein E (APOE) gene has been found to be a strong risk 
factor for AD [52, 53] as well as variants in genes like SNCA, MAPT and LRRK2 for 
Parkinson disease [54]. Furthermore, SNCA represent also an important risk locus for 
both multiple system atrophy and DLB [55, 56], as APOE for dementia with Lewy bodies 
[56] and MAPT for both CBD and PSP [57]. 
In the other hand, environmental factors including nutrients, pollutants, chemicals, 
metals, physical activity, and lifestyle, physical and mental stress can modulate 
epigenetic markers in developing organisms and adults. Thus, this may result in the 
alteration of gene expression through DNA methylation, histone modification, and non-
coding RNA-associated gene silencing, increasing the susceptibility risk to 
neurodegenerative diseases [58]. Indeed, it has been demonstrated that Presenilin 1 
PSEN1 expression can be modulated by modifying the methylation homeostasis, with 
consequent alteration of the amyloidogenic pathway, senile plaques burden and specific 
cognitive tasks in AD mice [59, 60]. Likewise, exposure to lead (Pb) could induce the 
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hypomethylation of CpG dinucleotide in the APP promoter leading to abnormal APP 
processing [61].  
Meanwhile, both Huntington's disease, ALS patients, as well as their respective mouse 
models showed DNA histone hypoacetylation that can ultimately trigger cell apoptosis 
and lead to neuronal death [62]. Regarding PD, the SCNA is potentially regulated by 
DNA methylation. Hypomethylation of the SCNA intron1 negatively correlates with its 
expression and was reported in the substantia nigra of affected patients [63]. miR-7 and 
miR-153 which negatively regulate alpha synuclein expression levels were also found to 
be reduced in PD brain [64]. There is evidence that exposure of humans or mice to the 
environmental toxins like MPTP, paraquat, or rotenone hinder mitochondrial function, in 
particular the complex I, which results in an elevated free radical production and 
oxidative stress leading to acute and irreversible Parkinsonism [65]. Furthermore, the fact 
that a single heterozygous mutation in the recessive PINK1 and Parkin genes could lead 
to PD in some patients, suggested that these heterozygous mutations raise sensitivity to 
environmental toxins that conjointly are enough to cause PD [66]. A study done to known 
about the concordance rate in twins for dementia with Lewy bodies (DLB) revealed a 
neuropathological discrepancy in the type of dementia between monozygotic couples 
hinting at the importance of environmental or epigenetic factors in Lewy body pathology 
[67]. Therefore, overall these data highlighted the interplay between aging, genetic and 
environmental factors in the etiopathogenesis of neurodegenerative diseases. 
According to increasing evidence and the molecular pathological classification of NDs, 
the gradual accumulation of misfolded protein aggregates in well-ordered structures, 
habitually called amyloid is thought to be at the root of these diseases [68]. This occurs 
within specific brain regions often showing significant neuroinflammation and increased 
oxidative stress with final degeneration of neural tissue [69]. Although there is, a clear 
difference between proteins aggregates implicated in distinct NDs, protein-misfolding 
procedure, its intermediates, final products, and principal characteristics are notably 
identical [68]. 
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Protein misfolding and aggregation 
 
Proteins are the operators of cellular functions and the correct folding of a protein into its 
native three-dimensional structure guarantees its biological functionality [70]. The 
sequence of amino acids as well as local low-energy chemical bonds between atoms in 
both the polypeptide backbone and the amino acid side chain determine the structure of a 
protein [71]. Indeed, following translation, each protein occurs as a specific sequence of 
covalently bonded amino acids, called polypeptide chain, which represent it primary 
structure. Then, depending on hydrogen bonds forming within the polypeptide chain, the 
latter can acquire an α-helix or β-sheet structure that constitute the secondary structure. α-
helix is formed when polypeptide chains twist into a spiral, whereas in β-sheets 
polypeptide chains run alongside each other. Furthermore, the α-helices and ß-sheets can 
fold into a compact conformation stabilized by hydrogen bonds or ionic interactions 
referring to the three-dimensional tertiary structure of a protein. The quaternary structure 
designates the number and arrangement of multiple folded polypeptide chains known as 
subunits in a multi-subunit complex Fig 1.1.  
 
20 
 
                                 
Figure 1.1 Level of Protein structure  
 
Thermodynamically, the folding process is represented as an energy funnel where the 
unfolded state is associated with more chaos, higher entropy, and free energy, which 
leads the protein to curve and twine in order to reach a maximum stability or lowest 
energy state: the three-dimensional native conformation [72]. However, the principal 
driving force of the folding process is due to the tendency of hydrophobic amino acids to 
cluster together within the protein in view of lessening the amount of hydrophobic side 
chains exposed to water [73, 74]. Given the importance and complexity of the folding 
process, incipient proteins are assisted by chaperones. Moreover, chaperones monitor the 
quality of folded proteins by either reorienting non-native species to their native state or 
targeting them for degradation through the ubiquitin proteasome system or via the 
autophagy pathway or sequestration into cellular compartments [75]. 
However, some proteins are devoid of a stable tertiary and/or secondary structure under 
physiological conditions, existing as dynamic ensembles of interconverting structures 
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termed intrinsically disordered proteins (IDPs) or hybrid proteins due to the presence of 
both structured domains and biologically important intrinsically disordered regions 
(IDRs). It therefore results in a unique structural plasticity and a conformational 
adaptability allowing these proteins/regions, to interact with a broad range of unrelated 
partners, hence, serving as hubs in cellular protein-protein interaction network [76]. 
Consequently, IDPs/IDRs are involved in numerous biological processes and their 
disregulation and/or misfolding can lead to potentially fatal pathologies. Indeed, most 
proteins involved in some neurodegenerative diseases also known as proteins misfolding 
diseases like α-synuclein, Aβ, prion, tau and TDP43 have been shown to contain 
IDRs[76]. The suppleness of this structural form is essential for the conformational 
reordering, driving the formation of the core cross-beta structure of the amyloid fibril, 
which is a common characteristic of misfolded proteins [71]. However, both natively 
folded proteins and IDPs can undergo misfolding and aggregation under certain 
conditions. While ordered or folded proteins need to be first destabilized before going 
through fibrillation, natively unfolded proteins has to be partially folded [77]. Effectively, 
the consequential mainly unfolded conformation ensures distinct intermolecular 
interactions, including electrostatic attraction, hydrogen bonding and hydrophobic 
contacts, which are required for oligomerization and fibrillation [78]. Thus, 
environmental partially denaturing conditions such as low/high pH, high temperature, 
agitation, elevated glucose or oxidative agents and change in metal ions can trigger 
protein misfolding [79]. Furthermore, there could be several other causes of protein 
misfolding listed below [80]:    
▪ somatic mutations in the gene sequence which induce the synthesis of a protein 
incapable to adopt the native folding underlying most of the inherited 
neurodegenerative disease. 
▪ errors on the processes of transcription or translation leading to the production of 
modified proteins unable to properly fold.  
▪ failure of the folding and chaperone machinery.  
▪ Mistakes on the posttranslational modifications or trafficking of proteins. 
Subsequently, misfolded proteins, in search of a lower energy levels and more stability, 
have a propensity to aggregate. Indeed, the misfolding process leads to the exposure of 
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hydrophobic fragments to the solvent while these fragments were ordinarily hidden inside 
the protein, resulting to a great rank of tackiness. Thus, the exposed hydrophobic 
fragments may interact with exposed hydrophobic patches of other proteins leading to the 
most favorable organization in the β-sheet structural motif of these protein aggregates 
[81, 82]. They can be classified in three categories ranging from small oligomers, 
intermediate protofibrils to large amyloid fibrils. Oligomers are soluble, low-molecular 
weight structures varying in size from dimers to decameters [83, 84] whose structural and 
biochemical characterization has been challenging due to their unstableness. However, 
evidence suggested that oligomers differ from primarily disordered [85] to structures 
similar to those of fibrils [86]. In particular, FTIR (Fourier-transform infrared 
spectroscopy) and NMR studies showed that oligomers are devoid of the parallel in-
register β-sheet structure present in fibrillar form, but they have the β-loop-β secondary 
and tertiary folds as in fibrils [87]. Some oligomers share common immunological 
epitopes which are recognized by conformational antibodies, A11 (spherical) and αAPF 
(annular) [88], while fibrillary oligomers are recognized by conformational antibodies 
OC [89]. Protofibrils are short, flexible, rod-like structures consisting of unbranched 
polymers with 4-11 nm width and can reach a length of 100mm. They show a high β-
sheet content and like the fibrils of which they are the direct precursors, they can bind the 
amyloid-specific dyes Congo red and thioflavin [90]. Amyloid fibrils are linear and 
unbranched structures of approximately 10 nm diameter and generally various 
micrometers in length. They show a classical “cross- β” X-ray diffraction paradigm 
consisting of two major reflections at 4.7 Å and 10 Å found on orthogonal axes [82].  
The mechanism of protein misfolding and aggregation comply with the so-called 
“seeding-nucleation” model first proposed by Jarret and Lansbury [91] and subsequently 
modeled kinetically in detail [92]. Accordingly, the initial step of misfolding is 
thermodynamically unfavorable and progresses slowly, until the formation of a minimum 
stable oligomeric unit: the nucleus or seed, which then rapidly grows by incorporating 
monomeric proteins to form larger polymers, the protofibrils an then amyloid fibril. 
Therefore, kinetics of amyloid formation can be plotted by a sigmoidal curve with a lag 
phase followed by rapid growth phase which reach a plateau or saturation phase. The 
slope of the elongation curve reflects the speed of the fibril formation, which can be 
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increased by addition of preformed seeds that reduce the length of lag phase and 
accelerate the grow phase. Indeed, during the process, off-pathway oligomers can be 
formed which do not finish in fibrils while prefibrillar or on-pathway oligomers do so. 
Furthermore, the mature fibrils, probably helped in vivo by mammalian Hsp70–Hsp40–
Hsp110 tri-chaperone system, macro-autophagy, and the proteasome system can shear or 
fragment to form fibrillar oligomers (originated from fibril) that can again aggregate [93]. 
It results in a secondary nucleation catalyzed by mature fibrils fragments that act as a 
template to form diffusible oligomers from monomers as illustrated in Fig 1.2.  
         
Figure 1.2 Illustration of amyloid protein fibrillation pathway. A nucleus is formed during the lag 
phase, and addition of monomer results in the formation of aggregates, which subsequently grow into 
mature fibrils. Preformed fibrils or fibril fragmentation may catalyze nucleation, and this is called 
secondary nucleation[94].  
 
Thus, based on the seeding nucleation model several in vitro assays have been generated 
for the production of synthetic amyloid fibril as experimental model and are used as 
diagnostic tool for the detection of protein misfolding diseases. The most used techniques 
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are protein misfolding cyclic amplification (PMCA) and real-time quaking-induced 
conversion (RT-QuIC). The PMCA protocol was firstly developed by Soto's group for 
the detection of PrPSc from various biological samples like brain homogenates (BH), 
urine, blood, cerebrospinal fluid (CSF) and saliva [95]. The protocol implies a sonication 
and incubation phase that alternate several times. The sonication allows the proliferation 
of template units while the incubation phase promote the expansion of aggregates. 
Finally, PK digestion and western blot (WB) analysis are used for the characterization 
and recognition of pathological aggregates. However, the fact that PMCA must be carried 
out in several rounds, combined with the need for immunoblot make it time-consuming 
assay. Thus, Atarashi and colleagues elaborated the QuIC assay by modifying the 
protocol of PMCA [96]. In the QuIC assay, the PrPC substrate originate from hamster’s 
brain homogenate is switched by recombinant PrPC and a strong intermittent shaking is 
used to promote seeded aggregation instead of sonication [97]. Of note, both assays 
necessitate the employment of discontinuous mechanical forces in order to mimic the 
fragmentation of newly formed fibrils, highlighting its importance since it produces 
thermodynamically unstable fibrils ends that act as seeds. In addition, as an alternative to 
WB analysis, the formation of β-sheeted aggregates is measured by Thioflavin T (ThT) 
fluorescence in real time as a read-out, hence the name RT-QuIC [96]. Furthermore, 
PMCA and especially RT-QuIC were found suitable for the detection and amplification 
of others misfolded protein aggregates like Aβ, α-syN, tau, and TDP43[98-101].  
 
Toxicity of misfolded proteins 
 
Once formed, misfolded protein aggregates can impair neuronal integrity leading finally 
to neurodegeneration. Their precise mechanisms of action are still unclear and seem to 
dissent depending on the protein species involved and whether the accumulation is intra 
or extracellular. Generally, misfolded proteins act by toxic gain-of function although 
loss-of-function effects are sometime observed. Extracellular aggregates like amyloid 
fibrils of Aβ and PrP might activate a signal transduction pathway that leads to apoptosis 
by interacting with specific cellular receptors as RAGE (receptor for advanced glycation 
end-products) [102]. Alternatively, their neurotoxic effects can be translated by 
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membrane disruption and depolarization mediated by ion-channel formation, ensuing the 
impairment of ion homeostasis and disfunction of cellular signal transduction, resulting in 
neuronal death. While intracellular aggregates might damage cells by recruiting factors 
that are essential for cell viability into the fibrillar aggregates [68]. Indeed, huntingtin and 
alpha synuclein aggregates usually contain components of the proteasome, chaperone 
proteins, cytoskeletal proteins, and transcription factors [103]. Beside of their proteotoxic 
effects, misfolded proteins may exert genotoxic effects by disturbing nuclear DNA 
replication and repair enzymes [104]. That leads to the impairment of the entire cellular 
interactome by jamming both the integrity of proteasome (proteostasis) and the genome 
[105]. Another consequence of misfolded protein aggregates is the generation of 
oxidative stress owing to the production of free radical species, which leads to protein 
and lipid oxidation, increasing of intracellular calcium and mitochondrial disfunction 
(Abramov et al 2020). Misfolded protein aggregates might trigger astrogliosis and 
microgliosis leading to neuroinflammation which is thought to be a double-edged sword 
since it can have both negative and positive effects simultaneously [106]. Furthermore, 
there is a co-interaction between protein misfolded aggregates and symptoms of cellular 
distress including calcium signaling abnormalities, mitochondrial dysfunction, oxidative 
stress, and neuroinflammation which in many cases worsen reciprocally. For instance, 
misfolded aggregates as amyloid-β, -syn, tau and mHtt are known to induce oxidative 
stress in neuron and or astrocytes [107] while, conversely, oxidative stress triggers 
protein misfolding, aggregation and proteostatic collapse[108]. Thus, it results in a 
vicious cycle that inevitably leads to neuronal death. It was firstly thought that misfolded 
aggregates in the form of amyloid fibrils were the neurodegeneration cause. However, 
increasing evidence suggests that oligomers could be the most neurotoxic species and that 
amyloid-like fibrils formation might be a way to isolate and protect the cell against toxic 
misfolded intermediates [83, 109, 110]. Indeed, oligomers, due to their smaller size, 
thermodynamic instability and their structural arrangement in particular the abnormal 
exposition of hydrophobic groups on their surface and the more number of open active 
ends [110] can easily diffuse and interact improperly with many functional cellular 
components like membranes and organelles [111]. Alternatively, both soluble misfolded 
intermediates and amyloid-like fibril aggregates might exert their toxicity through 
26 
 
different mechanisms. While soluble oligomeric species might trigger apoptotic-signaling 
pathways, amyloid-like aggregates might take up tissue space, damage neuronal 
connections and recluse essential cellular factors. In addition, some neurons might show a 
specific vulnerability to apoptotic stimuli triggered by different misfolded proteins, 
resulting in distinct cellular damage, which translates to an ineffective elimination of 
protein aggregates from these cells [68]. For example, dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) seem to be the population affected first in 
Parkinson's disease (Brichta et al 2014). However, even inside SNpc there is about 90% 
of dopaminergic neurons loss in the ventral tier compared to circa 25% dopaminergic 
neurons loss in the dorsal tier [112]. Conversely, dopaminergic neurons in the ventral 
tegmental area (VTA) degenerate in a lower amount [113]. Moreover, while cholinergic 
neurons in the basal forebrain and in the pedunculopontine nucleus are affected, 
GABAergic neurons in the same regions are not. Thus, GABAergic neurons indifferently 
of their location seems to resist to Lewy body pathology (Kingsbury et al 2010, Surmeier 
et al 2017). Another study using induced pluripotent stem cells (iPSCs) from patients 
harboring an APP mutation to quantify AD-relevant phenotypes, following directed 
differentiation to rostral fates of the brain and caudal fates showed that the rostral neurons 
are more vulnerable to the pathology compared to caudal neurons. Interestingly, authors 
found that both the generation of Aβ and the responsiveness of tau to Aβ were affected 
by neuronal cell type confirming the influence of cell-autonomous factors on selective 
neuronal/regional vulnerability [114]. Thus, the subsistence of diverse mechanisms of 
cellular toxicity may be related to the differences in the protein sequence, cellular 
emplacement and biophysical characteristics of the aggregates [109]. Finally, there is a 
dynamic equilibrium between misfolded intermediates, monomers and amyloid fibrils 
(Teplow 1998, Kim et al 2002), which accentuates the difficulty to distinguish the 
involvement of the different mechanisms into neurodegeneration.  
 
Propagation and transmission of misfolded proteins 
 
One of the common characteristics of neurodegenerative diseases rely on the highly 
predictable spatiotemporal patterns of the distribution of pathological proteins in the 
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brain of patients. For instance, in PD patients, alpha-synuclein pathology firstly appears 
in the olfactory bulb and the dorsal motor nucleus of the glossopharyngeal and vagal 
nerves. Then, the pathology propagates in a rostral direction from the brainstem to the 
midbrain and forebrain eventually reaching the cerebral cortex [22, 115]. In AD brains, 
pathological tau is primarily found in the locus coeruleus and transentorhinal cortex. 
Then it propagates to the entorhinal and hippocampal regions, followed by the basal 
temporal cortex and the insular cortex with an eventual reaching of the neocortex in the 
later stages of the disease [13, 116]. While Aβ pathology follows a different pattern of 
distribution, occurring first in the orbitofrontal neocortex and basal temporal cortex, and 
then spread throughout the neocortex with the ultimate attainment of the hippocampus, 
midbrain, brainstem and cerebellum [14, 116]. These patterns of distribution were 
historically attributed to vulnerability between brain regions [112] or the progressive 
spreading of pro- inflammatory cytokines [117]. However, several studies during the past 
decade have provided evidence for a “prion like” propagation of these pathogenic 
proteins that might be at the heart of the pathogenesis mechanisms of neurodegenerative 
diseases [118-122]. Indeed, the propagation rely on the intrinsic feature of these 
pathogenic proteins, to corrupt similarly the conformation of their physiological 
counterparts upon interaction with them. Such a phenomenon is peculiar to prion disease, 
which can be infectious, genetic, or idiopathic in origin [9]. The infectious agent 
represented by the misfolded prion protein (PrPSc), spreads the disease by acting as seeds 
to start up the misfolding and aggregation of the native, monomeric prion protein in the 
host [7]. Thus, the seeding nucleation mechanism combined with the resilience of 
aggregates to the cellular clearance machinery allow PrPSc to spread from cell to cell, 
throughout the central nervous system and sometimes even to the periphery. Generally, 
PrPSc propagation occur silently for a long period of time until achievement of toxicity 
limit required to spark cellular dysfunction, brain damage, and clinical disease [120]. 
Furthermore, PrPSc can be efficiently transmitted between hosts of the same species while 
the efficiency of the transmission is minimized between diverse species. This could be 
due to the discrepancies between amino-acid sequences of hosts and donors prevent PrPSc 
to trigger the conformational conversion of the native one leading to the so called 
“species barrier” [123, 124]. However, under certain conditions like a high sequence 
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homology, intrinsically unfolding and high flexibility of proteins the species barrier 
might be traversed [125]. A typical example of species barrier overcrossing refers to the 
BSE epidemic in Britain in the 1980s in cattle, which caused variant Creautzfeldt-Jakob 
disease (vCJD) in the humans due to natural transmission of prion diseases from 
livestock to humans after consumption of infected livestock [7, 126].  
Similarly, protein misfolding-related neurodegenerative diseases behave almost like 
PrPSc. Of note, the concept of prion-like behavior of these proteins was and still under 
significant debate since they are not strictly speaking “infectious” under natural 
conditions [122, 127]. Indeed, this was supported by studies showing no infective 
transmission between humans of AD and PD occurred in cadaver-derived human growth 
hormone (HGH) recipients [128] or blood transfusion recipients [129] as it should have 
been the case in classical prion diseases like CJD. However, other studies reported a 
potential transmission of Aβ-pathology via pituitary-HGH and dura mater transplants in 
recipients’ patients [130, 131]. Similarly, transmission of α- synuclein pathology was 
shown from the host to the graft in patients who have received transplants of human fetal 
brain-derived cells as a therapy for PD [132, 133]. Thus, further epidemiological and 
longitudinal studies will be of great help in clarifying the true infectious nature of protein 
misfolding related neurodegenerative diseases.  
Nevertheless, as enounced above, various studies using cellular and animal models of 
diseases have demonstrated that several NDs can be experimentally transmitted through a 
prion-like spreading. In fact, inoculation of brain homogenates from patients affected by 
NDs or transgenic mouse models rich in protein aggregates like Aβ, tau α-syn, results in 
the induction of disease pathology in the recipient cellular or animal models [134-137]. 
Moreover, injection of synthetic aggregates in wild type animals was able to induce a de 
novo pathology like infectious prions [138-141]. Indeed, Pathological induction can be 
lessened by decreasing the inoculum of protein aggregates [142-144]. Thus, the induction 
rate might be directly proportional to the amount of seeds as shown by titration 
experiments in some cases [145]. Furthermore, ALS and FLTD-related proteins, 
including SOD1 and TDP-43, have been shown both in stem-cell culture and animal 
studies to follow self-perpetuating seeded aggregation, congruent with prion-like 
transmission [146, 147]. Similarly, drosophila models of HD have proven evidence of a 
29 
 
prion-like spreading of Huntindton aggregates [148], as confirmed by further cellular and 
in vivo studies [119, 149]. Interestingly, peripherally disease transmission was shown 
even when seeds were administered systemically. In particular, repeated injections of α-
synuclein fibrils into the rodent tail vein and an intraperitoneal inoculation of tau extracts 
or amyloid beta seeds, triggers intracerebral aggregation of deposits and relevant 
pathology [150-154].  
Overall, these data combined with the previously discussed adaptability of PMCA and 
RT-QuIC techniques to the proteins misfolding related neurodegenerative diseases 
demonstrate that the seeding nucleation mechanism underpin the 
propagation/transmission of misfolded proteins confirming thus the prion like hypothesis. 
However, diverse subcellular pathways and cellular connections may contribute to the 
spreading process, to favor interaction between misfolded aggregates and the native 
protein. Misfolded aggregates can be sequestered in aggresomes which are targeted to 
elimination by macroautophagy and degradation into lysosomes [155]. In pathological 
conditions, the autophagy–lysosome pathway is dysregulated or inhibited [156, 157] 
allowing both autophagosomal and lysosomal vesicles to propagate aggregates within the 
cell, constituting thus a reservoir of misfolded proteins [155]. Both retrograde and 
anterograde axonal transport may be also a way of propagation of misfolded aggregates 
along neuronal processes [158, 159]. Misfolded aggregates can be release in the 
extracellular space upon cellular death or trough exocytosis [160]. Furthermore, 
exosomes can serve as a vehicle for the release and delivery of misfolded aggregates 
between cells [161]. Indeed, plasma and other body fluid are enriched of exosomes which 
could contribute to systemic spread of proteins misfolding related neurodegenerative 
diseases [162]. Growing evidence suggest that tunneling nanotubes, which are membrane 
bridges between cells for intercellular long-distance communication, may participate to 
the spreading of misfolded aggregates [163-165]. Then misfolded aggregates can be 
taken up from the extracellular space via diffusion, endosomes, receptor-mediated 
transport, or fusion of the transporting vesicles with the plasma membrane allowing 
entrance in the recipient cells [166-169]. In order to interact with their physiological 
counterparts and begin templated amplification, pathological seeds need to exit the 
endosomal vesicle once internalized in the recipient cells. In fact, a- Synuclein, tau and 
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mutant Huntington fibrils were shown to induce vesicle rupture to access the cytosol 
[170, 171].  
Intriguingly, pathological seeds composed by one misfolded protein were found to 
promote the polymerization and greatly accelerate the aggregation process of a different 
proteins [172]. This phenomenon acquaintes as cross-seeding or heterologous seeding 
and may explain the contemporaneous presence of different misfolded proteins 
aggregates, the occurrence of more than one PMD in the same individual (Fig 1.3). For 
instance, Aβ aggregates can seed the polymerization of prions and alpha-synuclein, 
which can lead to the increased polymerization rate of soluble Aβ [172]. Indeed, 50% of 
the AD patients display a-synuclein aggregates accompanied by more severe pathological 
symptoms [173]. Similarly, Aβ aggregates have been observed in typical prion plaques 
either in sporadic CJD or GSS syndrome cases [174, 175]. Moreover, Transgenic mice 
developing both Aβ, α-syn and tau deposits shown a strengthen cognitive decline which 
is thoroughly linked to the deposition of all three amyloidogenic proteins [176]. 
Therefore, cross-seeding phenomenon may be considered as modulator of 
transmission/spreading of misfolded proteins and might explain the fact that one Protein 
misfolding diseases (PMD) may be a risk factor for occurrence of a second PMD. 
Another important modulation factor of transmission/spreading pattern lies on the 
conformation of pathological seeds which will be discussed below. 
 
              
 
Figure 1.3 Illustration of cross-seeding between different proteins [109] 
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            The structural polymorphism of misfolded proteins and the related strain concept 
 
Initial results from X-ray analysis following investigations on the common cross-β 
structure of amyloid fibrils, shown a strict organization in which the β-strand direction is 
perpendicular to the fibril axis [177, 178]. However, recent progress in biophysical 
techniques led to the discovery that amyloid fibrils do not have a universal tertiary and 
quaternary structures [179],  occurring either as parallel [180, 181] or antiparallel β-sheet 
conformation[182, 183] and other structural elements.  Moreover, David Eisenberg and 
colleagues, in order to understand the precise composition of the β-cross structure, used 
X-ray microcrystallography to analyze small peptides that developed both microcrystals 
and fibrils. These fibrils were consisted of a pair of β-sheets where each β-sheet was 
formed by β-strands. One β-strand corresponds to a single peptide, and these β-strand 
peptides compose β-sheets with a close “dry” interface called a steric zipper. These steric 
zippers are repeated structures running up and down the fibril axis, excluding water from 
the interface between the β-sheets where the side chains of one β-strand are located 
between the side chains of another strand. Van der Waals interactions and hydrogen 
bonds between the side chains are the principal forces which lead to the formation of this 
interface [184]. Extending these observations to the structure of several amyloid proteins, 
Eisenberg and colleagues uncovered a difference between the basic organization of steric 
zippers in amyloid fibrils. Thus, they proposed eight possible structural classes of steric 
zipper (Fig. 1.4) based on three structural principles: first, whether their β-strands were 
antiparallel or parallel; second, whether the β-sheets were packed “face-to-face” or “face-
to-back”; and third, whether the orientation of the β-sheets was “up-up” or “up-down” 
with respect to each other [185].  
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Figure 1.4 | The eight classes of steric zippers. Two identical sheets can be classified by: the orientation 
of their faces (either face-to-face or face-toback), the orientation of their strands (with both sheets having 
the same edge of the strand up, or one up and the other down), and whether the strands within the sheets are 
parallel or antiparallel. Both side views (left) and top views (right) show which of the six residues of the 
segment point into the zipper and which point outward. Green arrows show two-fold screw axes, and 
yellow arrows show translational symmetry. Below each class are listed protein segments that belong to 
that class [185]. 
 
Interestingly, the same polypeptide can display steric zippers of different structural 
classes based on the experimental conditions. Therefore, a major fount of amyloid fibrils 
polymorphism could be due to the diversity of steric zippers that amyloidogenic 
sequences are able to develop [186]. The majority of the eight possible structural classes 
of steric zipper proposed by Eisenberg and colleagues were shown in amyloid proteins 
like insulin, tau, amyloid-β and prion [185]. Indeed, in prion diseases (PrDs), the protein 
aggregates show a structural heterogeneity which is due to ability of PrPSc to self-
propagate distinct ‘conformational variant resulting in diseases with different 
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characteristics including incubation period, individual patterns of PrPSc distribution and 
spongiosis, and relative severity of the spongiform modifications within the CNS. These 
conformational variants are termed prion strains, analogously to strains of classical 
infectious agents[187-189]. Various prion strains can maintain permanently their 
properties to the detriment of the normal prion protein, and this process has been 
replicated in a cell-free system in vitro, suggesting that strain variation is dependent on 
PrPSc properties [190]. However, the local brain environment may interfere in the 
generation of protein strains. Different intracellular environments could affect both the 
initial protein misfolding process and the templated amplification process. This could lie 
on the affinity level between seeds and physiological monomer present in different 
intracellular environments as well as the strong assimilative capacity of the seed [191]. 
Interestingly, auxiliary substances present in the intracellular environments can both 
modify the intrinsic properties of the protein by forming or breaking covalent bonds such 
as PTMs and truncation and also influence the fibril assembly by noncovalent binding of 
extrinsic factors such as chemical metabolites, lipids, poly (ADP-ribose) (PAR) and 
metal ion [192-195]. Moreover, in pathological seeds composed of a mixture of different 
conformations or strains, there could be a selection and amplification of a specific 
conformation from the mixture, depending on the optimal adaptability to the host’s 
biological environments [196] (Fig 1.5). This process may induce the disappearance of 
the old strain and the appearance of a new strain resulting thus in a phenomenon termed 
strain evolution [197, 198]. 
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Figure 1.5 generation of different pathological protein strains. Different intracellular environments can 
result in different pathological protein strains and several potential mechanisms for this differentiation have 
been suggested. a | Different intracellular environments could affect the initial protein misfolding process. b 
| Different intracellular environments could affect the templated amplification process. c | If pathological 
seeds were a mixture of different conformations or strains, different intracellular environments could lead 
to the selection and amplification of a specific conformation from the mixture [196]. 
 
Similarly, to prion strains, strains like-behavior have been observed for several protein 
misfolding related neurodegenerative diseases. Indeed, initial in vitro generation of Aβ 40 
fibrils that undergone agitation step or not resulted in different structures. Aβ 40 fibrils 
subject to agitation have a predominantly ‘striated-ribbon’ morphology, while fibrils 
grown without agitation have a predominantly ‘twisted ‘morphology. In addition, the two 
kinds of fibrils show different neurotoxicity in cell culture [199]. Subsequent fibrillation 
of Aβ using seed from two different AD patients exhibiting different neuropathology and 
clinical history, have led to the production of two structurally diverse Aβ forms, 
confirmed by Electron microscopy and solid-state NMR techniques[200]. Using strictly 
controlled in vitro fibrillation conditions it was possible to produce Aβ 40 and Aβ 42 
providing further evidence of the existence of Aβ strains [201]. Thus, it has been 
proposed at least two distinct strains of Aβ in AD patient brains which are serially 
transmissible during serial passages in mice [202]. 
Furthermore, a comparative study of the topographical distribution of protein amyloid 
lesions showed differential clinical profiles of various disorders in tauopathies, 
synucleinopathies, and TDP-43 proteinopathies [203]. Indeed, at least seven different 
diseases have been associated with the accumulation of tau aggregates, including AD, 
frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, 
argyrophilic grain disease, and chronic   traumatic encephalopathy [204]. While PD, 
multiple system atrophy, and Lewy body dementia have been linked to the accumulation 
of alpha synuclein aggregates [205]. Analogously to prion strains causing diseases, 
tauopathies and synucleinopathies can be discriminated by the clinical symptoms, brain-
region-specific pathology, and preference of the aggregates to accumulate in different cell 
types and/or by the distinct morphological and biophysical characteristics of the 
aggregates, their toxicity, and their seeding ability [204-206]. Kaufman, and colleagues 
35 
 
isolated and characterized 18 different tau strains in a cell culture model, each of which 
displayed different biochemical and biological properties[207]. After inoculation of 
transgenic mice with these strains, they found strain-specific intracellular tau aggregates 
in distinct cell types and brain regions, exhibiting different rates of propagation [207]. 
Thus, different tau species can self-propagate, resulting in distinct neuropathological 
presentations as found in human tauopathies and supported by another study where 
different tau strains were isolated from 29 patients affected by five distinct tauopathies 
[208]. Cryo-electron microscopy allowed the construction of atomic models of tau 
aggregates which are organized either as paired helical or straight filaments. Filaments 
are made of two identical protofilaments spanning residues 306–378 of tau, which adopt 
a combined cross-β –β -helix structure. Paired helical and straight filaments differ in their 
inter-protofilament packing, providing a model to explain how the same protein can 
adopt different conformational variants [206]. Indeed, Cryo-EM studies showed that at 
the atomic level, Tau fibrils isolated from the brains of patients afflicted by various 
tauopathies including AD, Pick’s disease, CBD, and chronic traumatic encephalopathy 
(CTE) display distinct folds of Tau molecules and fibrillar assemblies [195])[206, 209-
212] (Fig 1.6). Likewise, structural differences between α-syn fibrils purified from the 
brains of patients with MSA and DLB have been observed after cryo-EM analyses [213]. 
Interestingly, brain extracts from MSA patients but not from PD or DLB patients induced 
α-syn aggregation in mice expressing α-syn (A53T) mutation suggesting that MSA is 
caused by a strain of α-syn, which is different from those causing PD or DLB [214]. It 
has been found that Lewy bodies (LBs) in the substantia nigra showed biochemical 
differences from LBs in neocortical areas of patients afflicted by PD with dementia 
(PDD), which is a particular form of PD, [215]. Even within the same disorder of MSA, 
α-syn display distinct early foci of aggregation in different clinical cases of striatonigral 
degeneration and with olivopontocerebellar atrophy although converge with longer 
disease duration [216]. Thus, there could be a presence of different abnormal 
conformations within the same pathological condition. α-syn prominently accumulates 
into cytoplasmic inclusions in oligodendrocytes of the brain in MSA whereas it found 
majorly as neuronal inclusions in PD and DLB [27]. It has been demonstrated that α-syn 
in glial cytoplasmic inclusions is more potent than that in Lewy bodies in terms of 
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neuropathology and seeded propagation [217]. Again, this study highlighted the influence 
of different cellular environments on the generation and effect of α -syn strains. 
Analogously, inducing α -syn aggregation in vitro in the presence of distinct 
concentrations of salts results in either cylindrical fibrils or flat, twisted ribbons [218]. 
Detailed characterization of these alternative structures has made it possible to observe a 
big difference in terms of proteolytic resistance, secondary structure, X-ray fiber-
diffraction patterns, distribution of secondary structure elements determined by solid-
state NMR, cellular toxicity, in vitro seeding, and propagation in mammalian cells [218]. 
Further evidence indicates the existence of multiple different conformations for others 
misfolding protein-related neurodegenerative disorders, including SOD1[219] and 
Mutant HTT [220]. Overall, these data show that Different conformations of the same 
pathological protein can display dramatically different seeding capacities and spreading 
patterns, leading to the pathological and clinical diversity of neurodegenerative disease. 
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Figure 1.6 Environment-sensitive amyloid fibril formation of Tau (a) and α-syn 
Proteins(b)[195]. 
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II- ΑLPHA-SYNUCLEINOPATHIES  
 
The abnormal accumulation of alpha synuclein protein in distinct cellular populations of 
the brain is a common pathological feature of synucleinopathies. However, the variety of 
cell and brain structures involved as well as different clinical manifestations observed in 
affected patients even though with some overlapping symptoms, constitute the basis for 
differential diagnosis and categorization. 
 
1.Parkinson disease 
 
PD is the most widespread form of α-synucleinopathies with an overall prevalence of 
0,3%, 1.0% in people over 60 years old and 3.0% in people over 80 years old [221]. Men 
are more affected than women, with a ratio of 1.5 to 1.0 respectively [222]. The rates of 
incidence of PD are estimated among 8 and 18 per 100 000 persons/year [222]. Thus, by 
the year 2030, there will be 8–9 million subjects in the world suffering from this disease 
[223]. As the majority of NDs, it is prevalently a sporadic disease, however with 10-15% 
of familial forms. The genes responsible of familial form are known as "PARK" with 
different number following the order of identification. Up to know, 23 PARK genes have 
been linked to PD with mutations showing either autosomal dominant (e.g., SCNA, 
LRRK2, and VPS32) or autosomal recessive inheritance (e.g., PRKN, PINK1, and DJ-1) 
[224]. In addition, exposure to some environmental toxin like 1-methyl-4phenyl-1, 2, 3, 
6-tetrahydro-pyridine (MPTP), the herbicide paraquat and the pesticide rotenone have 
been linked to the development of PD [225, 226]. The diagnosis of PD is based on 
clinical manifestations including cardinal motor symptoms, like bradykinesia, rigidity, 
rest tremor, postural and gait impairments [227]. According to the features of motor 
symptoms, PD can be distinguished in the tremor-dominant PD, which is relatively 
absent of other motor symptoms, and the non-tremor-dominant (akinetic/rigid) PD, 
including phenotypes as akinetic-rigid syndrome and postural instability gait disorder. 
Moreover, some PD patients show a mixed or an indeterminate phenotype having several 
motor symptoms of comparable severity [228, 229].The tremor-dominant PD patients 
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often exhibit a slower rate of progression and less functional disability than the non-
tremor-dominant PD [230]. Besides motor symptoms, various non-motor symptoms have 
been observed in PD patients. These include olfactory dysfunction, cognitive impairment, 
psychiatric symptoms (depression, visual hallucinations, and anxiety), insomnia, rapid 
eye movement (REM) sleep disorder (RBD) [231], autonomic dysfunction (constipation, 
orthostatic hypotension, and urinary incontinence), pain, and fatigue. Cognitive 
impairment includes specific cognitive domains such as visuospatial or executive. 
Symptoms, like impaired olfaction, constipation, depression, excessive daytime 
sleepiness, and RBD, appear well before the onset of the motor symptoms [232]. The 
non-tremor-dominant PD patients exhibit autonomic deficits early [233, 234]. The loss of 
pigmented dopaminergic neurons in the SNpc and the formation of a-syn-containing 
intraneuronal inclusions represent the main pathological hallmarks of PD. SNPc 
dopaminergic neuron death induces the disruption of the nigrostriatal pathway with a 
reduction of dopamine levels in the striatum, resulting in the occurrence of the cardinal 
motor symptoms of PD. However, neuronal loss has been also observed in various other 
brain areas such as the locus coeruleus, the nucleus basalis of Meynert, the dorsal motor 
nucleus of the vagus nerve, the pedunculopontine nucleus, the VTA, the raphe nuclei, and 
also the hypothalamus and the olfactory bulb [235]. Other neurotransmitter systems 
including the cholinergic, adenosinergic, glutamatergic, GABAergic, noradrenergic, 
serotonergic, and histaminergic also undergone degeneration [236].  This is thought 
responsible of some of the non-motor symptoms of PD that do not respond well to 
dopamine replacement therapies [237], even though the precise pathological mechanisms 
underlying the non-motor symptoms in PD are still relatively unclear. 
 α-syn-containing intraneuronal inclusions can occur either in the in neuronal somata and 
neurites and are named respectively LBs and LNs, or collectively known as Lewy related 
α-syn pathologies (LRP) [238, 239]. LB are round, eosinophilic inclusions consisting of a 
granular and fibrillar hyaline core with a surrounding halo (Fig 1.7). They size can range 
from 5 to 30 µm in diameter, and numerous LB can be found inside a single neuron 
[240]. According to literature, LB are subdivided in 2 types: classical brainstem and 
cortical LBs which are devoid of the halo, have less distinct outlines, and have usually 
small size. In SN, structures like  cortical LBs are sometimes called “pale bodies” and are 
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considered LB precursors [241]. Filamentous a-synuclein is the main components of LB 
followed by, several proteinsn including ubiquitin, tau, parkin, heat shock proteins 
(HSPs), oxidized/nitrated proteins, cytoskeletal proteins (such as neurofilaments, MAPs, 
and tubulin), proteasomal and lysosomal elements, and others [242].  
In 2003, Braak and colleagues proposed a staging scheme of PD based on the 
topographical location of LRP as previously described (see classification of NDs) A 
further revision of Braak hypothesis proposes that LRP may in fact be initiated in nasal 
and intestinal mucosal sites, specifically in the olfactory bulb and the enteric cell plexuses 
(“dual-hit hypothesis”) [243]. 
 
2. Dementia with Lewy Body 
 
DLB is the second major synucleinopathy, and the most frequent cause of degenerative 
dementia after Alzheimer’s disease [244]. It accounts for about 5% of all dementia cases 
in older populations [245] with a mean age of appearance of 75 years, ranging from 50 to 
80 years. there is a small male predominance and a mean disease duration of 9 years, 
ranging from 1 to 20 years [246]. Approximatively, 70% of cases are sporadic while 
30%are familial [247] with the convincing involvement of gene like APOE, GBA and 
SNCA [248]. Of note, DLB belongs to Lewy bodies disorders which are dementia 
syndromes associated with Lewy bodies and are subdivided into DLB, AD, PD, and 
PDD, usually used to define the cognitive impairment occurring in people diagnosed with 
Parkinson’s disease [249]. The timing of dementia relative to parkinsonism allow the 
clinical distinction between PDD and DLB. indeed, DLB is diagnosed when cognitive 
impairment precedes parkinsonism or begins within a year of parkinsonism while PDD is 
diagnosed when parkinsonism precedes cognitive impairment by more than 1 year [250]. 
The main clinical features of DLB are fluctuating cognition (periods of inattention 
interspersed with periods of lucidity, with deficits involving the naming of objects, verbal 
fluency, visuospatial abilities, and executive functions), complex visual hallucinations, 
parkinsonian motor features and REM sleep behavior disorder (failure to enter paralysis 
during REM sleep and subsequent physical acting of dreams) [251]. Additional features, 
such as severe autonomic dysfunction, hallucinations outside of the visual modality and 
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depression may also appear. The occurrence of widespread limbic and cortical Lewy 
bodies and Lewy neurites composed of aggregates of α-syn, as well as the loss of 
midbrain dopamine cells and loss of cholinergic neurons in ventral forebrain nuclei are 
shared neuropathological feature of DLB and PDD [252]. However, some differences 
have been observed. Indeed, most of DLB cases display an advanced Braak stage, with 
cortical involvement [26]. In contrast to PD, in DLB patients the degeneration of 
dopaminergic neurons in the substantia is less pronounced with a relative lack of D2 
receptor upregulation in the striatum [253]. Moreover, there is a significant amyloid 
deposition in the striatum, hippocampus and cortex [238, 254] of several patients  with 
co-occurrence of Aß and tau pathology  at postmortem observations in some patients 
[255, 256]. 
 
3. Multiple system atrophy 
 
MSA is a neurodegenerative disease that encompasses disorders such as 
olivopontocerebellar atrophy, Shy–Dragers syndrome, and striatonigral degeneration. The 
mean onset age varies from 40–60 years old with male predominance [257]. It has been 
estimated that there is about 3–4 cases per 100,000 person  in the age group 50–99 years 
per year [258] with an average survival time of 6–10 years after onset [257]. MSA is 
essentially a sporadic disease with genes like MSA – SNCA, COQ2, MAPT, GBA1, 
LRRK2 and C9orf72 which have been identified as susceptibility genes [259]. MSA is 
characterized by parkinsonism, cerebellar ataxia, autonomic failure, motor weakness, and 
cognitive decline [260]. Additional symptoms may include autonomic failure and 
parkinsonism or cerebellar syndrome [261]. Based on the motor phenotypes it possible to 
distinguish parkinsonian (MSA-P) and cerebellar (MSA-C) forms. MSA-P seems to 
predominate in Europe (58%), with respect to MSA-C that dominates in Asia (84%) 
[262, 263]. MSA-P patients exhibit a hypokinetic-rigid parkinsonian syndrome, which 
tends to be more symmetrical and less responsive to Levodopa than in PD, with an 
irregular, higher-frequency postural tremor. In MSA-C, the most common symptom is 
gait ataxia with wide-based movements. Furthermore, ataxia of the limbs, cerebellar 
oculomotor impairments, scanning dysarthria, and intention tremor are common in MSA-
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C [264]. As in PD and DLB, MSA is pathologically characterized by the presence of 
alpha synuclein inclusions throughout the brain. However, in MSA α-synuclein filaments 
accumulate prevalently in the cytoplasm and nuclei of glial cells. We distinguish glial 
cytoplasmic inclusions (GCIs) in oligodentroglia which is the most diffuse, nuclear 
inclusions (GNIs), neuronal cytoplasmic inclusions (NCIs), neuronal nuclear inclusions 
(NNIs) [265].  
Given the unwavering presence of abnormal aggregates of alpha synuclein in LRP and 
GCIs (Fig 1.7), the main pathological hallmarks of the above described 
synucleinopathies, it is well accepted that alpha synuclein may play key role in their 
pathogenesis even though its physiological function is not yet well defined. 
 
 
Figure 1.7 Neuropathology of α-synuclein deposits in different synucleinopathies. 
α-synuclein aggregates stained by anti-α-synuclein antibody showing different aggregates morphologies and distinct 
affected areas in PD (SN: substantia nigra), DLB (Ctx: cortex) and MSA (CB: cerebellum; GCI: glial cytoplasmic 
inclusion 
 
4. Alpha-synuclein protein: structure localization and physiological functions 
 
α-syn, together with beta-synuclein, and gamma-synuclein belong to the evolutionary 
conserved synuclein family that share a highly conserved alpha-helical lipid-binding 
motif with other protein like apolipoproteins, 14-3-3 chaperones and several small heat-
shock-proteins [266]. In humans, SNCA is localized on chromosome 4, position 4q22.1 
where it is organized into 10 exons, with a size vary from 42 to 110 base pairs and length 
of about 117 kb. α-syn protein exist at least in 4 different alternative splicing variants for 
functional polypeptide synthesis [267].  The prevalent variant is a 14kda polypeptide 
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made of 140 amino acid residues 20 whose primary structure is characterized by three 
different regions (Fig 1.8): 
▪ The amino-terminal sequence going from residue 1 to 60 that contains the 
hexamer conserved repeats consisting of 11 residues with the consensus sequence 
KTKEGV which refers to highly conserved alpha-helical lipid-binding motif. It is 
also in this portion of the protein that were found the A30P, A53T, and E46K 
mutation sites related to familial PD cases. 
▪ A central hydrophobic region of residues 61to 95, known as NAC (non-amyloid-β 
component) since it was firstly purified from Alzheimer’s disease senile plaques 
of patients [268]. This domain contains two additional KTKEGV motifs and is 
specific to the alpha synuclein among the synuclein family [269]. The NAC 
domain was found to promote alpha-synuclein fibrilization, suggesting its 
importance for the protein aggregation [270]. Indeed, mutation of only one single 
amino acid within NAC can alter the aggregation properties of the protein [271]. 
▪ The carboxy-terminal sequence, from residue 96 to 140, is highly negatively 
charged, enriched in proline residues, and is used for interaction with metals, 
small molecules, proteins, and other α-syn domains [272]. In fact, the ability to 
interact with the NAC domain gives it a regulatory role in the aggregation and 
fibril formation of the protein. Moreover, it is responsible for the intrinsically 
disordered nature of α-syn since it lacks rigid well-defined structure [273]. 
Importantly, the phosphorylation site at Ser129 is localize in the C terminal region 
and this major post-translational modification is a main pathological hallmark in 
synucleinopathies [274]. 
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Figure 1.8 Schematic representation of α-syn regions. The amino-terminal from amino acids 1–60 is an 
amphipathic region responsible for α-syn-membrane interactions. It contains the hexamer conserved repeats 
represented by the red rectangles, and the A30P, E46K, and A53T PD linked mutations. The central region 
from amino acids 61-95, termed NAC (non-β amyloid component), is the most hydrophobic portion of the 
protein and is required for the aggregation process. The C-terminal from amino acids 96–140 is 
characterized by the presence of acidic residues and several negative charges. The residue serine 129 in this 
region is phosphorylated in Lewy bodies. (B) Schematic representation of micelle-bound α-synuclein. The 
N-terminal region with antiparallel α-helices is shown in blue, the NAC region is also an α-helix and is 
shown in orange, and the unstructured C-terminal part is shown in red. Numbers refer to amino acid 
residues. Modified from [275]. 
 
Numerous studies using different biochemical and biophysical methods demonstrated 
that α-syn purified from bacteria, red blood cells, mammalian cell lines, human and 
rodent brain exists predominantly in a partially unfolded monomeric state, hence it 
belonging to the IDP family [276, 277]. However, it has also been reported that in 
physiological conditions when α-syn binds to lipid vesicles or membranes, it can adopt an 
helically folded tetramer form of 58 kda which is resistant to aggregation [278]. In 
particular, the N-terminal portion of the protein acquires the α-helical conformation, 
extending it in helix or antiparallel helices connected by a short linker, depending on the 
membrane properties, while the C-terminal portion remains unstructured, as illustrated in 
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Fig 1.8 B [279, 280]. Moreover, Wang and colleagues have shown that recombinant α-
syn, produced in bacteria and purified under nondenaturing conditions, forms stable 
tetramers in vitro in the absence of lipid bilayers or micelles. These oligomeric forms of 
a-syn are resistant to fibrillation, do not readily form pores in membranes, and are not 
toxic to cells [281]. Together these data suggest that that native α-syn exists in 
equilibrium between different conformational and/or oligomeric states and this 
equilibrium can be influenced in vivo by several factors that were shown to modulate α-
syn structure and oligomerization in vitro such as post-translational modifications, 
oxidative stress, proteolysis, concentration of lipids and metal ions [282]. Thus, α-syn 
occurs prevalently as a partially unstructured monomer which can possibly forms a stable 
multimer and/or adopt different structures under specific stress-induced conditions or 
upon interaction with other proteins, specific ligands, lipids and/or biological membranes, 
probably required for it physiological functions. 
α-syn owes its name to Maroteaux and colleagues who first identified it in synapses and 
the nucleus in the torpedo ray [283]. It is highly expressed in the nervous system 
including neocortex, hippocampus, substantia nigra, thalamus, and cerebellum, but it is 
also present in erythrocytes, platelets, and as well as in other tissues [284]. α-syn is 
prevalently a neuronal protein but can also be found in the neuroglial cells and represents 
about 1% of cytosolic protein in the brain [285]. As an IDP, alpha synuclein may serve as 
a hub in protein interaction networks, being central to the normal function and stability of 
the network. Indeed at least 69 proteins have been found as alpha synuclein interactors 
[286], and this makes coherent its diverse subcellular localization even though its 
physiological function in each subcellular compartment is not well understood. For 
example, in the nucleus it may interact with histones and affect histone acetylation, 
thereby modulating gene expression [287, 288]. Moreover, α-syn can bind DNA, induce 
DNA fragmentation, and modulate repair processes [289, 290]. α-syn has been found in 
the mitochondria where it acts in part like a physiological regulator of mitochondrial 
fusion. α-syn binds to curved membrane sites on the outer mitochondrial membrane 
(OMM), blocking the fusion stalk buildup, a necessary structure for mitochondrial fusion, 
thus favoring mitochondrial fission [286]. α-syn is also associated with endoplasmic 
reticulum (ER) and Golgi membranes [291] where it is involved in the regulation of 
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endoplasmic reticulum and Golgi vesicle trafficking. It was recently demonstrated that a 
fraction of α-syn is localized in mitochondria-associated membranes, a region mainly 
composed of intracellular lipid rafts, which interconnects the ER with mitochondria 
[292]. It is also present in the endolysosomal system [293]. 
Results from numerous interaction studies led to the involvement of α-syn in regulating 
synaptic neurotransmission, function, and plasticity [282, 285, 294, 295]. At the 
presynaptic terminal, asyn associates with synaptic vesicles [285], binds membranes 
[296] and induces membrane curvature [297]. α-syn regulates soluble NSF attachment 
protein receptor (SNARE) complex assembly [298] by binding the SNARE protein 
synaptobrevin-2/vesicle-associated membrane protein 2 (VAMP2) to promote synaptic-
vesicle fusion [299]. Furthermore, α-syn was shown to help stabilize vesicles by 
protecting them from premature fusion with target membranes as a result of curvature 
stress [300]. α-syn can also modulate the late steps of exocytosis. In fact, this was 
confirmed by a study showing a rescue of the assembly and function of exocytic 
SNAREs after transgenic expression of α-syn in mice lacking cysteine string protein 
alpha (CSPα)[298]. Since CSPα is a presynaptic chaperone, these findings suggested that 
α-syn can act as a chaperone as well. Indeed, α-syn has the ability to inhibit thermally 
induced protein precipitation [301] and as described above share structural motif with and 
binds to 14-3-3 proteins, a family of molecular chaperones [302]. In addition of showing 
decreased levels of the SNARE protein SNAP-25 and impaired SNARE complex 
assembly, mice lacking CSPα display a strong neurodegeneration, suggesting a link 
between these events [298].  
Several studies also reported an involvement of α-syn in dopamine (DA) biosynthesis and 
release. Indeed, in the presynaptic terminals of neurons α-syn was shown to interact 
physically with tyrosine hydroxylase (TH), the rate-limiting enzyme in DA synthesis, 
leading to the inhibition of the TH activity [303]. α-syn can increases the ratio of the less 
active, non-phosphorylated form of TH to the more active phosphorylated form through 
the activation of protein phosphatase 2A (PP2A)[304]. In addition, it has been found that 
α-syn can physically interact with human dopamine transporter hDAT and modulate 
dopamine reuptake [305, 306]. Other physiological functions have also been ascribed like 
an anti-apoptotic function against several insults, including oxidative stress and serum 
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deprivation [307-309] and involvement in cellular differentiation via ERK/MAPK 
pathways [310]. 
 
5. alpha synuclein: role in pathology  
 
As reported above, α-syn is thought to play a key role in the pathogenesis of 
synucleinopathies where it adopts an amyloid like structure and aggregates in the 
patients’ brains. As for the others misfolding proteins related neurodegenerative diseases 
the aggregation process follows the seeding nucleation model previously described. It has 
been found that α-syn filaments within pathological inclusions display a core which 
extends over about 70 amino acids, including the repeat region of a-synuclein (residues 
30–110)[271, 311]. High resolution structure obtained by solid-state nuclear magnetic 
resonance, scanning transmission electron microscopy and X-ray diffraction, revealed 
that the core residues of the a-synuclein fibril were organized in parallel, in register ß-
sheets with the topology of a Greek key common to amyloid structures [312]. 
The exact cause of α-syn aggregation is still unknow but various factors were shown to 
influence such process. Given the implication of SNCA mutations as cause of familial 
forms of PD, it has been suggested that these mutations can have an impact on the protein 
structure increasing the α-syn propensity to aggregation. Indeed, Ala53Thr, Ala30Pro, 
and Glu46Lys which are three PD-related point mutations have been shown to accelerate 
a-syn aggregation [313, 314], probably through changes in net charge, hydrophobicity 
and secondary structure propensity, leading to the destabilization of the long-range 
interactions in the α-syn  monomer [315]. NMR spectroscopy allows to discover that the 
Ala30P substitution strongly attenuates the helical propensity in the N-terminal region, 
possibly resulting in a decreased interaction between α-syn and lipid membranes [316]. In 
addition, β-strand formation does not necessarily require the involvement of proline, thus 
the introduction of a proline residue in the N terminus, slows the incorporation of the N 
terminus in the fibrils resulting in an increased oligomer formation [273]. The Ala53Thr 
mutation was suggested to expend the region of β-sheet structure in the NAC domain 
leading to increased intermolecular contacts that induces an elevate tendency to form 
oligomers. Moreover, this mutation also stabilizes the β-sheet structure in the mature 
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fibril, explaining the faster rate of formation [273]. However, The Glu46Lys mutation 
does not disrupt long-range interactions even though a-SYN with this mutation has an 
increased fibrillization rate [317]. It was suggested that this increased fibrillization rate 
may be due the overall change in net charge [318]. Moreover, glutamate residues in the 
Lys-Thr-Lys-Glu-Gly-Val (KTKEGV)-type repeats (such as Glu46) may be greatly 
involved in the regulation of α-syn fibrillization [313]. Increased level of α-syn 
concentration because of triplication or duplication of SNCA increase the probability of 
oligomer and fibril formation[273]. 
Post-translational modifications like phosphorylation (Ser87, Tyr125, and Ser129), 
ubiquitination, oxidative modifications, have been suggested to have an effect on 
aggregation. Among them the most recurrent is the phosphorylation at residue Ser129 
whom site is positioned within the C-terminal region of α-syn and G-protein-coupled 
receptor kinase, casein kinases 1 and 2 were suggested as the responsible kinases [319] . 
Only 4% of native α-syn is phosphorylated under physiological conditions, while in LRP 
this percentage increases to approximately 90%, highlighting its importance as 
pathogenic event [320, 321]. Subsequent studies confirmed the promotor effect of the 
phosphorylation at residue Ser129 in α-syn aggregation [322, 323]. Nevertheless, the 
phosphorylation of the Ser87 induces an expansion of α-syn structure, increasing its 
conformational flexibility, and blocking its aggregation in vitro. Similarly, the 
phosphorylation at Thr125 attenuates the conversion of α-syn to toxic oligomers [324]. 
Therefore, based on the sites involved, phosphorylation may increase or decrease the 
fibrilization potential of α-syn.  
Accordingly, the ubiquitination process, in particular the position of the modified 
residues was also suggested to influence α-syn aggregation. Ubiquitin is a small protein 
that can be linked to lysine (Lys) residues of target proteins that must be proteolytically 
degraded by proteasome complex. There are 15 lysine residues in α-syn structure and 
only Lys6, Lys10, and Lys12 were shown to be involved in vivo [325]. It has been found 
that the modification of Lys6 induced a slower aggregation respect to the un-
ubiquitinated protein [326], while the multiple lysine modification induced the formation 
of an aggregated toxic form [325]. 
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In COS-7 cells, an unidentified Lys residue located at the N-terminal part of α-syn 
protein was shown to be modified by SUMO1 which is a small ubiquitin-like modifier 
promoting α-syn aggregation [327]. 
Oxidative modifications including tyrosine (Tyr) and methionine (Met) oxidation can 
influence α-syn aggregation. Indeed, tyrosine cross-linking following exposure to 
oxidative agents promotes the α-syn oligomerization and inhibits its transition to 
fibrils[328]. The methionine-oxidized protein has been shown disrupts “end-to-end 
association” of α-syn necessary for fibril growth and thus guides its aggregation toward 
less structured, non-toxic oligomers [329]. 
Also, nitration is thought to influence α-syn aggregation. Beside the fact that nitrated α-
syn was found in LBs [330], nitrated α-syn was found to accelerate fibril formation of 
unmodified α-syn [331].  
In addition, environmental factors like metal ions, pesticides were shown to accelerate the 
fibrillation rate of α-syn [332].   
 
6. Mechanisms of a-synuclein neurotoxicity 
 
Even though some issues remain to be clarified regarding to the precise mechanisms 
through which α-syn aggregation induce neurodegeneration, various toxic mechanisms 
have been linked to the α-syn aggregation process, oligomeric and fibrillar products. 
Given the principal localization and function of α-syn at the synapse, the aggregation 
process might lead to a loss of function resulting in synapse dysfunction. Indeed, it has 
been found that α-syn large oligomers bind to synaptobrevin-2 and disrupt SNARE 
complex formation by obstruction of vesicle docking [333]. In addition, the binding of α-
syn aggregates with vesicles induces clusters formation that constrains physiological 
vesicles trafficking [334]. The formation of pores on the vesicles surface may be another 
consequence of the interaction between oligomeric α-syn and vesicle which leads to 
neurotransmitter leakage [335, 336]. Overexpression of α-syn in nigral dopamine neurons 
resulted in reduction of dopamine reuptake and defective DAT function, thus a disruption 
of dopamine turnover [337]. 
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Mitochondria has been also suggested to be a cellular target for α-sync neurotoxicity. 
Indeed, overexpression of both α-syn A53T or WT induced an increased release of 
cytochrome c from the mitochondria and its accumulation in the cytosol was also 
associated with increased caspase-3 and-9 activities over time [338] which could further 
lead to apoptosis. In addition, increased level of α-syn has been linked with higher 
concentrations of mitochondrial Ca2+, that triggers apoptotic pathways [339]. Similarly, 
soluble, prefibrillar α-syn oligomers, were shown to decrease the retention time of 
exogenously added Ca2+, promoted Ca2+-induced mitochondrial swelling and 
depolarization, and accelerated cytochrome c release. Interestingly, these mitotoxic 
effects of α-syn were mitochondrial complex I dependent [340]. Indeed, it has been found 
that α-syn oligomers can also inhibit the import of proteins, including some subunits of 
complex I, into the mitochondria by binding to the translocase of the outer membrane 
(TOM20) and inhibiting its interaction with the co-receptor TOM22 [341]. Cells 
overexpressing α-syn, shown a high level of mitochondrial ROS that could impair 
mitochondria functions by decreasing the mitochondrial membrane potential [342]. 
Intriguingly, the impaired mitochondria ROS production can induce α-syn expression, 
oligomerization, and aggregation via oxidative damage [330, 343]. ROS produced during 
mitochondrial dysfunction, such as in complex I inhibition may increases the 
vulnerability of mutations in mitochondria DNA (mtDNA) given the proximity between 
the mitochondrial electron transport chain (ETC) and mtDNA [344] and especially 
considering mtDNA is not protected by histone proteins as seen in nuclear DNA [345]. 
Coherently, α-syn overexpression was linked to mtDNA damage [346] and mitophagy 
[347]. Alternatively, α-syn toxicity may indirectly induces mitochondrial dysfunction 
decreasing levels of the mitochondrial biogenesis factor PGC-1α as shown in cell models 
that express oligomeric α-synuclein, mice that express A30P α-synuclein [348] and the 
brains of patients with PD [349]. 
Considering the important role of the ER in protein folding, trafficking to the Golgi, 
calcium buffering, overexpression, or accumulation of mutant α-syn within the ER, may 
interfere with protein folding and induces ER stress, which may contribute to 
neurodegeneration via activation of cell death cascade [291]. In fact, elevated ROS levels 
owing to ER stress and mitochondrial dysfunction contribute to A53T α-syn-induced cell 
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death [338]. Toxic α-syn oligomers were found within the ER/microsome compartment, 
after examination of postmortem tissues of human PD patients and mouse cases of α-
synucleinopathy, supporting a direct pathological link between α-syn oligomers and ER 
stress in vivo [291]. Moreover, accumulation of α-syn in the ER induces calcium leakage 
into the cytosol which in turn promote further α-syn aggregation [350, 351]. Aggregated 
forms of α-syn induce the impairment of the ubiquitin-proteasome system which leads to 
ER stress and triggers the unfolded protein response [352, 353]. 
α-syn accumulation can induce defects in ER-Golgi trafficking, by both sequestering 
Rab1, a central regulator of membrane trafficking and activating transcription factor 6 
(ATF6) which prevents the vesicular transport to the Golgi [354]. Recently it has been 
found that α-syn can directly affect the Golgi apparatus, by inducing it fragmentation, as 
part of apoptotic cascade [355]. 
Autophagy is a cellular process which allows the degradation of damaged organelles, 
invading microorganisms, and aggregated proteins [356]. Overexpression of α-syn in 
SKNSH cells was shown to disturb autophagy by reducing autophagosome synthesis 
trough sequestration of Rab1 [357].  Moreover, A53T and A30P α-syn have a stronger 
binding affinity for the lysosomal receptor LAMP2A respect to WT α-syn, suggesting a 
defections degradation of  mutant forms of α-syn by protein clearance mechanisms, 
which results in increased α-syn burden of chaperone-mediated autophagy (CMA) and 
inhibits the loading and clearance of other cargo [358]. CMA can be also blocked by 
dopamine-modified α-synuclein, which might contribute to selective dopaminergic 
vulnerability in PD [359]. α-syn preformed fibrils (PFFs), were shown to induce 
defective lysosomal fusion and autophagic cargo accumulation [360], when incubated 
with neurons even though autophagosomes formed normally. It has been suggested that 
these defects might be due to an impaired autophagosome axonal transport [361]. Indeed, 
α-syn may partially disrupt axonal transport by interacting with tau protein that stabilizes 
and promotes microtubule assembly [362] or disrupts actin turnover and actin waves 
along axons, owing to cofilin inactivation [363]. Given the link between efficient 
autophagic degradation and lysosomal enzymatic activity, α-syn accumulation may 
potentially affect the correct lysosomal activity. In fact, in iPSCs from PD, it has been 
found that overexpression of α-syn reduced the enzymatic activity of multiple lysosomal 
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enzymes, like GCase, which is fundamental for the correct functioning of the auto-
phagolysosom [364, 365].  
Importantly, the presence of α-syn in MAMs [292], structures that mediate several key 
processes such as Ca2+ signaling, mitochondrial and ER stress, macroautophagy, and lipid 
synthesis may explain how α-syn accumulation may lead to cellular pathologies [366]. 
Of note, the diversity of pathway that are involved in α-syn neurotoxicity may be 
explained by the fact that distinct pathways might be affected in different 
synucleinopathies at different time points of disease progression. In addition, these 
differences might be intensified by differences in α-syn strain characteristics, specific cell 
types affected and diverse protein interactions accordingly to it prion-like behavior. 
 
7. Prion-like spreading of α-syn: insight from cells and animal models of 
synucleinopathies. 
 
Based on the hypothesis that α-syn has a key role in the pathogenesis of the 
synucleinopathies, a number of paradigms have been generated over the last two decades 
entailing different methodologies, such as duplication, triplication or genetic mutations in 
the α-syn gene (A53T, A30P, E46K, G51D, etc.), all linked to autosomal dominant PD, 
leading to the development of multiple transgenic PD models [367-370]. These models 
have the advantages to express α-syn at moderate, near-physiological or supra-
physiological levels for long periods as it occurs in the disease, allowing the study of 
disease-relevant pathways and the assessment of therapeutic interventions for familial 
forms of PD [371, 372]. However, transgenic PD models do not appear to recapitulate 
other pathological hallmarks of the disease, including the robust nigrostriatal 
degeneration and the consistent motor deficits [373, 374]. For some decades, neurotoxic 
models have been used, based on the intracerebral injection of the hydroxylated 
dopamine analogue 6-hydroxydopamine (6-OHDA) in rodents [375] or MPTP in non-
human primates [376], both leading to a rapid nigrostriatal degeneration associated to 
robust, well characterized motor deficits [377]. However, none of these models appears 
to display α-syn and LBs/LNs pathology [371, 378]. Therefore, toxin models are 
preferred for the assessment of symptomatic therapies or the study of sporadic forms of 
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PD. In order to model both hallmarks, i.e., the nigrostriatal degeneration, α-syn and 
LBs/LNs pathology, viral vector-based models of PD have also been generated [379]. 
When viral vector-mediated overexpression of WT or mutant human α-syn is targeted to 
the nigrostriatal system of naïve mice or rats, this induces a robust degeneration of 
nigrostriatal system with aggregation of the pathological α-syn forms [380, 381]. 
However, in these models the time course of the pathology is often relatively short (1-2 
months) and the α-syn aggregation is limited to nigrostriatal circuits while in PD subjects, 
the α-syn pathology seems to be time-dependent and widespread through the brain [22]. 
Moreover, the viral vector-based models of PD require a supra-physiological level of α-
syn overexpression to produce a robust PD phenotype, which is in contrast with the 
findings in the human condition [382]. A recent model was generated based on the prion-
like spreading of α-syn. Indeed, the Braak staging of α-syn pathology progression first 
suggested a prion like spreading between neurons, but molecular evidence was only 
provided by the discovery of α-syn pathology in grafted neurons in PD patients. The 
similarity in spreading with prion diseases was confirmed by the observation that α-syn 
inclusions in these neurons were positively stained for thioflavin-S, ubiquitin and were 
proteinase k resistant [383, 384] being also phosphorylated at serine129 [274] Moreover, 
the affected transplants showed reduced levels of dopamine transporter and tyrosine 
hydroxylase suggesting a spreading of PD pathology from host to graft neurons. 
It has been also found that MSA or PD patient-derived brain homogenates could induce 
pathological α-syn deposition when injected in recipient cells, or in the brain of mice and 
monkeys [214, 385] confirming the prion like mechanism. Accordingly, the α-syn pre-
formed fibrils (α-syn PFFs) were developed through the conversion of recombinant 
monomeric α-syn protein to a pathologic fibrillar form. Several studies shown that under 
certain conditions like incubation at 37°C, buffer, pH, and shaking conditions, the 
monomeric α-syn converts into β-sheet rich fibrils similar to those found in 
synucleinopathies [386, 387]. The resulting assemblies can either be added to the culture 
media or microinjected into the brain [388-391]. Indeed, in previous studies α-syn PFFs 
have been observed to become detergent-insoluble, able to trigger p-Ser129 α-syn 
pathology, synaptic dysfunction, perturbations in cell excitability, and induce cell death 
in both cell lines overexpressing α-syn as well as primary neuronal cultures from WT 
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mice [392, 393]. Interestingly it has been proven that α-syn PFFs were not able to trigger 
LB like aggregates and related cellular pathological events in neurons non expressing the 
α-syn protein endogenously [393]. Moreover, Sacino and colleagues after performing 
mixed neuronal-glial cultures from P0 C3HBL/6 mice showed that WT and mutant 
recombinant α-syn fibrils were able to recruit endogenous α-syn into morphologically 
distinct inclusions in neurons, providing a further proof of the prion-like self-templating 
mechanism of α-syn pathology [394].  The same authors also provide evidence that α-syn 
inclusion pathology can be passaged in primary astrocyte cultures. Similarly, to other 
reported studies, the aggregates formed were partially ubiquitinated, phosphorylated (p-
Ser129) and stained by ThS dye. This study also pointed out the existence of α-syn 
strains, that replicated in morphologically distinct inclusions. Furthers studies generated 
α-syn PFFs strains. In fact, using different salts concentrations Bousset and coworkers 
developed two strains exhibiting different structures, levels of toxicity, in vitro and in 
vivo seeding and propagation properties [218]. Other strains were generated in the 
presence or absence of lipopolysaccharide (LPS). These strains showed distinct 
molecular features and degradation/internalization kinetics by neurons and microglia 
[395], thus pointing out the involvement of environmental factors in the generations of α-
syn aggregates. Moreover, they confirmed previous suggestions according to which 
different cell types in the brain, such as oligodendrocytes, astrocytes, and microglia, can 
uptake α-syn assemblies [396, 397]. Therefore, the spreading of α-syn aggregates can 
occur not only between neurons, through several mechanisms. Indeed, as previously 
described above, α-syn aggregates shared several mechanisms of transfer between cells 
with others misfolded proteins. An alternative pathway is the misfolding-associated 
protein secretion pathway (MAPS), that involves the recruitment of α-syn to the ER-
associated deubiquitylase USP19, which is later encapsulated into late endosomes and 
secreted to the extracellular space[398]. It has been also found that the uptake of 
pathological forms of α-syn can be mediated by receptors, such as lymphocyte activation 
gene 3 (LAG3) [399], or heparan sulfate proteoglycans [400]. In addition, membrane 
proteins like the α3 subunit of the Na+/K+-ATPase (Shrivastava et al., 2015), the Fc 
gamma receptor IIb [401], or neurexin 1α [399, 402] are known to interact with different 
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of α-syn species at the cell surface. Interestingly recent studies discovered the cellular 
prion protein as potential sensor of α-syn aggregates [403, 404]. 
When switching to the in vivo model, α-syn PPFs showed a better representation of 
synucleinopathies respect to the previous models. Indeed, injections of α-syn pre-formed 
fibrils into the rodent Striatum, Somatosensory Cortex, EC, Olfactory Bulb, SNpc, or 
muscle have been shown to produce inclusions that closely resemble those found in PD 
and DLB, not only in the proximity of the injected sites but also in distally located, and 
anatomically related, brain areas, suggesting a widespread propagation of α-syn 
pathology [388, 405]. Intramuscular injection induced spinal motor neuron degeneration 
and the loss of neuromuscular junctions [406], suggesting that α-syn PFFs can act also 
through retrograde transport from the injection site [407]. Intravenous injection in non-Tg 
rats revealed the α-syn deposits in the CNS after 4 months (in cortical neurons, spinal 
cord), indicating that the peripheral injection leads to the crossing of the blood-brain 
barrier (BBB)[154]. Interestingly, accordingly to the gut-brain hypothesis of α-syn 
propagation Kim and colleagues showed that gut injection of α-syn PPFs converts 
endogenous α-syn to a pathologic species that spread to the brain resulting in features of 
Parkinson’s disease. However, vagotomy and α-syn deficiency prevent the 
neuropathology and neurobehavioral deficits induced by transmitted pathological α-
synuclein [408]. This study provides further proof of the prion like gut-brain spreading of 
α-syn pathology, validating the α-syn PPFs model. 
In addition, α-syn PPFs model exhibited altered behavior along with neuropathological 
changes. Indeed, injections into the rodent Striatum or Olfactory Bulb have been shown 
to induce a progressive loss of dopaminergic neurons in the SN with a further appearance 
of motor and/or olfactory impairments akin those seen in the human condition [388, 405, 
409-413]. 
By contrast, it seems like deficits and abnormalities in learning and memory behavior are 
spared in the α-syn PFF models up to 6 months after injection. This could be due to 
the injection site (such as the striatum, olfactory bulb, and peritoneum) and/or the 
duration of pathological spreading [414]. Therefore, further investigations are required. 
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8. Hippocampal α-syn pathology  
 
The hippocampus is a part of brain belonging to the limbic system and encompasses 
several structures, including the dentate gyrus, the CA1-CA3 layers, and the subiculum. 
The entorhinal cortex (EC), located in the parahippocampal gyrus, is considered as part to 
of the hippocampal region because it serves as the main ‘‘interface’’ between the 
hippocampus and other parts of the brain [254]. The hippocampus is known to play 
important roles in the consolidation of new memory, emotional responses, navigation, 
and spatial orientation which are frequently impaired in synucleinopathies [254]. Indeed, 
PD is clinically characterized not only by motor deficits but also by cognitive 
disturbances affecting both executive functions and memory [415] that may lead to overt 
dementia in 30 to 40% of the patients as the disease progresses [13, 416]. In addition, 
memory impairment is often a prominent hallmark of DLB which shares numerous 
features with AD and PDD [417-419]. While brainstem LBs are thought to contribute to 
motor symptoms, the neural substrate for cognitive symptoms in synucleinopathies 
remains a matter of debate. Cykowski and colleagues shown that the occurrence of 
globular NCIs in the neocortex was associated with cognitive impairment [420]. In 
contrast, other authors found that 33 out of 102 (i.e., about 33%) autopsy-proven MSA 
patients developed some degree of cognitive impairment and had a greater burden of 
NCIs in the dentate gyrus rather than the neocortex, compared to those without cognitive 
impairment[421]. 
Consistent with Braak hypothesis which suggests a caudal to rostral spread of LB/LN 
pathology from the brainstem to cerebral cortex [22], several studies have reported that 
cortical or limbic LBs/LNs are the best correlate of dementia in PD [422-426]. However, 
other studies pointed out no correlations between cognitive dysfunction and the 
distribution of LBs in the brain [427-429]. In a previous study, the deficits in reference 
memory observed following neurotoxic ablation of dopaminergic neurons in the Ventral 
Tegmental Area (VTA) were seen to affect also working memory when cholinergic 
neurons in the Medial Septum/vertical limb of the Diagonal Band of Broca (MS/vDBB) 
were targeted as well, suggesting that both neuron systems might be critical for the 
regulation of specific aspects of memory function [430]. Moreover, it has been 
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demonstrated that similar behavioral deficits could be obtained independently of 
dopaminergic and cholinergic cell loss following targeted overexpression of human WT 
α-syn in these regions in rats using recombinant adeno-associated viral vector, suggesting 
that a severe α-syn pathology in target regions such as the hippocampus may induce 
substantial effect on behavior [431]. Indeed, like in DLB patients, some genetic mouse 
models overexpressing α-syn display predominant cortical and hippocampal pathology 
with associated deficits in hippocampal function as impairment of contextual fear 
memory and long-term spatial memory in the Morris water maze, as well as deficit in 
amygdala functions like cued fear memory, at middle or old age (8-9 months at the 
earliest) [432-434]. Interestingly, the notion of a possible involvement of hippocampal 
LB pathology in cognitive impairments is further supported by a recent study in patients 
with autopsy confirmed DLB where the degree of post-mortem Lewy pathology in 
hippocampal CA1 and EC was seen to correlate with their impaired cognitive 
performance while alive [435]. Similarly, Miki and coworkers found that neuronal 
cytoplasmic inclusion burden in the hippocampus and parahippocampus was linked to the 
occurrence of memory impairment in multiple system atrophy [436]. Surprisingly, 
however, no study to date has addressed the anatomical, molecular and functional effects 
of α-syn PFFs following injection in the hippocampus, a region known to be crucial for 
learning and memory. 
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                                                                                                                        CHAPTER II 
 
AIM OF THE STUDY 
 
Cognitive deficits represent common significant non-motor manifestations of 
synucleinopathies including Parkinson’s disease, dementia with Lewy body and multiple 
system atrophy. Besides being social and economic burden for community, such deficits 
are firstly known to deteriorate daily living activities leading to reduced independence, 
quality of life, and survival of affected patients. The anatomical and neuronal substrates 
underlying cognitive impairment are still poorly understood despite the multitude of 
studies already carried out. Considering the previously described results and limitations, 
the present study sought to investigate the progressive pathologic alterations and 
spreading of synthetic a-syn fibrils bilaterally injected into the hippocampus of adult rats, 
up to the onset of memory impairments. 
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                                                                                                                                  CHAPTER III 
 
                                      MATERIALS AND METHODS  
 
1.Expression and purification of recombinant mouse α-syn 
 
α-syn was prepared as described previously [437]. Briefly, recombinant α-syn protein 
was purified from Escherichia coli BL21 (DE3) cells expressing mouse α-syn construct 
from the pET11a expression vector. E. coli cells were grown in minimal medium at 37°C 
in the presence of ampicillin (100 g/ml) until OD600 of ≈0.6, followed by induction with 
0.6 mM IPTG for 5 h. The protein was extracted from periplasm by osmotic shock, 
followed by boiling for 20 min and ammonium sulfate precipitation. The protein was next 
purified by anion exchange chromatography (HiTrap Q FF column, GE Healthcare), and 
fractions were analyzed by SDS-PAGE. Finally, the protein was dialyzed against water, 
lyophilized, and stored at -80°C. 
 
2. Fibrillation of mouse α-syn  
 
Prior to fibrillation, the protein was filtered (0.22 µm syringe filter) and the concentration 
was determined by absorbance measured at 280 nm then the fibrillation was performed as 
described previously [403]. Briefly, purified mouse α-syn (1.5 mg/ml) was incubated in 
the presence of 100 mM NaCl, 20 mM Tris-HCl pH 7.4. Reactions were performed in a 
black 96-well plate with a clear bottom (Perkin Elmer), in the presence of one 3-mm 
glass bead (Sigma) in a final reaction volume of 200 µl. Plates were sealed and incubated 
in BMG FLUOstar Omega plate reader at 37°C with cycles of 50 s of shaking (400 rpm, 
double-orbital) and 10 s of rest. After fibrillation, the reaction mixtures were 
ultracentrifuged for 1h at 100 000g (Optima Max-XP, Beckman), sonicated for 5 min 
(Branson 2510) and resuspended in sterile phosphate-buffered saline (PBS), aliquoted 
and stored at -80 °C until use. The resulting α-syn fibril assemblies were then structurally 
characterized by atomic force microscopy (AFM) as previously described [403]. 
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3. Animals and experimental groups  
 
Thirty-six young adult female Sprague-Dawley rats (provided by the animal facility at the 
University of Trieste) weighing 220-250 g at the time of surgery were housed in high 
efficiency, particulate air-filtered, double-decker cage units (Tecniplast, Italy), and 
maintained under standard conditions of temperature, light and humidity, with ad libitum 
access to food and water. The animals were randomly assigned to groups receiving 
bilateral intrahippocampal injections of recombinant mouse α-syn PFFs (n=18) or 
phosphate-buffered saline (PBS) alone (sham-injected, n = 10) whereas the remaining 
animals (intact, n = 8) were not injected and served as unoperated controls. Subgroups of 
randomly selected animals (5 α-syn-treated, 3 sham-injected and 2 intact rats) were 
formed to be sacrificed at about 7- and 9-months post-surgery, whereas the remaining 
subjects (8 α-syn-treated, 4 sham-injected and 4 intact rats) were allowed to survive up to 
12 months post-injection. Behavioral analyses were begun at about 3 months post-
injection and consisted in the sequential administration of tests specifically designed to 
evaluate sensory-motor, as well as spatial reference and working memory abilities. Upon 
completion of the last testing session, at each of the predetermined time-points, the 
animals were sacrificed, and the brains processed for quantitative immunohistochemistry 
or western blot analyses (Fig 3.1). All the experimental procedures were carried out 
following the Italian Guidelines for Animal Care (D.L. 116/92 and 26/2014) which are in 
compliance with the European Communities Council Directives (2010/63/EU) and were 
approved by the Ethical Committee at the University of Trieste. 
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Figure 3.1 Experimental time-line diagram illustrating the temporal sequence of surgery, behavioral 
tests, killings, and the intervals between them. 
 
4. Surgical procedures 
 
Stereotaxic injections of recombinant, freshly sonicated mouse α-syn PFFs bilaterally 
into the hippocampus were performed on rats under deep anesthesia (sodium 
pentobarbital, 40 mg/kg, i.p.). Briefly, 7.5 µg of the protein was injected using a 10 µl 
Hamilton microsyringe (Hamilton, Bonaduz, Switzerland), in a volume of 5 µL sterile 
PBS per side at the following stereotaxic coordinates according to Paxinos and Watson 
[438] : AP = - 3.6; ML = ± 1.8; DV = - 3.6 (in mm, relative to bregma and outer skull 
surface). The dose and volume were chosen based on the results of pilot experiments. 
Each infusion was carried out over 5 min, waiting for additional 2 min before withdrawal, 
in order to prevent backflow and reduce tissue damage. For sham treatment, sterile PBS 
was injected using the same coordinates, volume and speed. 
 
5. Behavioral tests 
 
Starting from about 3 months post-injection, the animals underwent a battery of 
behavioral tests (normally administered between 9.00 am and 3.00 pm) conducted at 
different time-points, in order to evaluate possible effects of the treatments upon sensory-
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motor and cognitive functions and their time course (Fig 3.1). All the behavioral 
paradigms were based on modified versions of the water maze task originally developed 
by Morris [439] for the assessment of spatial learning and memory in rodents. The test 
apparatus consisted of a circular pool, 140 cm in diameter and 50 cm deep, filled with 
room temperature water to a depth of 35 cm and located in a room with several external 
cues that could be used for orientation. Four equally spaced points (conventionally 
indicated as North, South, East, and West) served as start locations, also dividing the tank 
into four quadrants. A circular platform (10 cm in diameter) was fixed to the bottom of 
the pool with it top 2 cm below (and thus invisible from) the water surface. In the middle 
of each quadrant, a circular area of about 20 cm in diameter (termed annulus) indicated 
the site where the escape platform could have been, if placed in that quadrant. For each 
animal, the latency to find the hidden platform, the distance swum, and the swim speed 
were recorded by a computer-based video tracking system. 
Three different paradigms, designed to evaluate the sensory motor, as well as reference 
and working memory abilities [440, 441], were implemented. 
 
6. Cued test  
 
All animals first received a free 60-second swim to become familiar with the swimming 
pool, followed by a 3-day cued learning session to exclude the occurrence of 
noncognitive (e.g. visual) deficits, induced by the treatment, that may interfere with the 
correct execution of the test. During the cued task, the position of the escape platform 
was made visible by a 10x15 cm striped flag and randomly changed on each of 4 daily 
trials.  
 
7. Morris water maze test 
 
Three days after conclusion of the cued test, the animals were subjected to the Morris 
water maze test for the assessment of reference memory. The animals were given four 
trials per day over five consecutive days with a 30 s intertrial time. On each trial, the 
animal was released into the pool from one of the starting points and then given 60 
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seconds to locate the platform (constantly kept in the North-East, NE, quadrant) and 
climb onto it. If the submerged platform was not found, the rat was gently guided by the 
experimenter and left on it for about 30 s, prior to be placed in the next predetermined 
starting point, whose sequence was defined randomly, and it was changed every day. On 
the fifth day of testing, after the fourth trial, the platform was removed and a spatial probe 
trial commenced, during which the animals were allowed to swim freely for 60 s. In this 
test, generally used to evaluate the efficiency of the previous learning, the distance swum 
as well as the collisions with the annuli in each of the four quadrants, were recorded. In 
order to check for possible delayed long-term effects of the α-syn treatment upon 
reference memory, a separate 3-days Morris water maze test, with a spatial probe trial, 
was administered to the animals just before sacrifice, at about 12 months post-injection. 
 
8. Radial Arm Water Maze Test  
 
Spatial working memory was tested using a radial arm water maze (RAWM) apparatus 
consisting in 6 swim alleys (50 cm length x 20 cm wide, numbered 1 to 6) radiating out 
of an open central area in the same pool. The submerged escape platform was placed at 
the end of an arm (referred to as the goal arm) and its position was changed every day 
over five consecutive days. In each of the 5 daily trials, the animals were released from a 
different starting position and given up to 60 secs to locate the hidden platform with a 30 
s intertrial time. Entering an incorrect arm (i.e. an arm that did not contain the platform or 
an already visited arm) was counted as an entry error. For each trial, the latency to find 
the platform and the number of arm selection errors prior to locating the goal arm were 
recorded. The task design entails that the animals locate the platform by chance on the 
first trial each day (and thus no group difference is expected), whereas in the second and 
subsequent trials the acquired information on the novel platform location for that day 
would determine substantial improvements in performance. Therefore, differences in 
latency or error scores between trials 1 and 2 across days, both in absolute terms and as 
percentage of trial 1 (savings) provided measures of working memory performance. 
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9. Two-trial radial arm water maze test 
 
In the original 5-trials-a-day paradigm, the RAWM testing is conducted over 5 
consecutive days, allowing animals to get used to the task contingencies and to exclude 
all the unspecific factors that may affect performance. In this case, the RAWM standard 
paradigm was modified by cutting the general duration of the test from 5 to 2 days, as the 
animals were already well habituated to the environment and have learned the rules of the 
task. In addition, the number of trials administered every day was reduced from 5 to 2 as 
it was noticed previously that the main improvement in the RAWM performance mainly 
occurs between the first and second trial. Thus, from 5 months post-injection and 
onwards, two 2-trial RAWM tests were administered over two consecutive days each 
week, organized as two adjacent blocks of 6 weekly sessions each.  Starting from 
approximately the 9th month post injection, the animals received the same two 2-trial 
RAWM testing sessions, but every second week, until significant group differences in the 
savings for both latency and errors were detected over three consecutive testing sessions. 
Subsequently, the delayed 3-days Morris water maze test was administered, as mentioned 
above (see also Fig3.1).  
 
10- Postmortem procedures  
 
Upon conclusion of behavioral tests, at about 7- and 9-months post-injection, the animals 
under terminal anesthesia (chloral hydrate 350 mg/kg i.p.) were perfused through the 
ascending aorta with room temperature saline, followed by ice-cold phosphate-buffered 
4% paraformaldehyde (pH 7.4). The brains were rapidly removed, kept in the same 
fixative for 2 hours and then transferred in a phosphate-buffered 20% sucrose solution at 
4°C until they had sunk. Coronal sections at 40 µm thickness were cut using a freezing 
microtome (Leitz Welzlar) from the prefrontal cortex level through the basal forebrain to 
the level of the caudal hippocampus and collected into 6 series. The sections were then 
stored at –20 °C in a phosphate-buffered antifreeze solution containing 30% glycerol and 
30% ethylene glycol, pending immunohistochemical analysis.  
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Animals allowed to survive up to 12 months post-injection, under terminal anaesthesia as 
above, were perfused through the ascending aorta with room temperature saline. After 
rapid removal, and using a counterbalanced left–right dissection schedule, the whole 
hippocampus, the prefrontal, fronto-parietal and entorhinal cortices from one hemisphere 
were dissected free onto a chilled glass plate, immediately frozen in crushed dry ice and 
kept at –80 °C for Western blot assay (see below). The remaining portions of the brain, 
which comprised the cortical and hippocampal regions from the opposite hemisphere, 
both striata and the entire basal forebrain were fixed by 24 h immersion in ice-cold 
phosphate-buffered 4% paraformaldehyde (pH 7.4), soaked in phosphate-buffered 20% 
sucrose and then cut as above. 
 
11. Immunohistochemistry  
 
For the detection of PK resistant α-syn aggregates, one series of free-floating coronal 
sections were first quenched in 3% H2O2 and 10% methanol for 10 minutes to eliminate 
endogenous peroxidase activity, and then treated 30 min with 5μg/ml of PK. After 
blocking unspecific binding sites with 5% normal goat serum (NGS, Immunological 
Sciences), and 0.3% Triton X-100 in phosphate-buffered saline (KPBS, pH 7.4) for 2 h, 
the sections were incubated overnight with a rabbit anti-α-syn primary antibody (C20-R, 
Santa Cruz, 1:500), 2% NGS and 0.3% Triton X-100 in KPBS. Subsequently the sections 
were incubated with a biotinylated secondary antibody (goat anti-rabbit 1:300, Vector), 
2% NGS and 0.3% Triton X-100 in KPBS for 1 hour. After this step, the sections were 
incubated with avidin biotin peroxidase complex (Vectastain ABC alite kit, Vector) for 
one hour and then reacted with 0,025% diaminobenzidine and 0.01% H2O2 in KPBS for 
3-5 minutes. The sections were mounted on gelatin-coated slides, dehydrated through 
steps in ascending alcohol concentrations, clarified in xylene and coverslipped for 
subsequent microscopical analyses. In order to ensure consistency during morphometric 
analyses (see below), tissue processing and staining were carried out under identical 
conditions, using all relevant sections at a time. Control tissue specimens, not exposed to 
the primary antibody, were also used to check for nonspecific labelling. All steps were 
performed at room temperature. 
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For double immunofluorescence, free-floating sections were incubated overnight at room 
temperature with a rabbit anti-phospho-α-syn (Ser129) (D1R1R) primary antibody (Cell 
Signaling, 1:1000) and a monoclonal mouse anti-GFAP antibody (SIGMA, 1:400). The 
sections were then incubated with an Alexa 488-conjugated goat anti-rabbit secondary 
antibody (Life Technologies, 1:200) and then with an Alexa 594-conjugated goat anti-
mouse (Life Technologies, 1:200) for 2 hours in the dark. The 4′,6-diamidino-2-
phenylindole (DAPI, Sigma 1:200) compound was used for nuclear staining. Slides were 
coverslipped with Fluoromount™ Aqueous Mounting Medium (Sigma) and images were 
acquired using a Leica confocal microscope (Leica TCS SP2, Wetzlar, Germany).  
 
12. Western blotting 
 
The cortices and the hippocampi dissected for the measurement of non-phosphorylated, 
Ser129-phosphorylated α-syn and PrPc expression levels, were homogenized using a 
manual dounce homogenizer in a RIPA (radioimmunoprecipitation assay) buffer 
containing 150 mM NaCl, 0.1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS 
(sodium dodecyl sulphate), 50 mM Tris-HCl (pH 8.0), 1× phosSTOP (Roche Diagnostic) 
and 1× protease inhibitor cocktail (Roche Diagnostic). The homogenates were 
centrifuged at 10000 rpm for 10 min at 4 °C and the supernatants collected and stored in 
aliquots at -80 °C until use. Total protein content of brain homogenates was measured 
using bicinchoninic acid protein (BCA) quantification kit (Pierce) and 25 μg/ml of brain 
homogenates were resuspended in Laemmli loading buffer, boiled for 5 min at 100 °C for 
denaturation. Subsequently the samples were loaded onto the Mini-PROTEAN® TGX™ 
Precast Gels (Biorad), transferred to PVDF membranes (Immobilon-P, Millipore) and 
incubated for 30 min with 4% PFA in PBS to better detect endogenous Ser129-
phosphoryated α-syn [442]. By contrast, no PFA treatment was employed for the 
detection of non-phosphorylated α-syn and PrPc. After incubation, the membrane was 
washed in TBS-T (0.1% Tween 20 in TBS) for 10 min, treated with 5% non-fat milk or 
BSA (w/v, in PBS) blocking solution for 1 h at room temperature in agitation and then 
incubated overnight at 4 °C with the following primary antibodies: rabbit polyclonal anti-
phospho S129 α-syn (Abcam, ab59264 1:1000);  rabbit polyclonal anti-α-syn (C-20-R, 
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Santa Cruz,  1:1000); mouse monoclonal anti PrPc (clone P, kindly provided by Prof. S. 
Prusiner, San Francisco 1:1000) and a mouse monoclonal anti β-actin (1:50000, A3854 
Sigma-Aldrich), all diluted in blocking solution.  
Membranes were washed with TBST and incubated in horseradish–peroxidase (HRP)-
conjugated goat anti-rabbit (DAKO, 1:1000) or goat anti-mouse (DAKO 1:1000) 
secondary Ab for 1 h. The membranes were washed in TBST, and proteins were 
visualized following the manufacturer’s instructions using Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare) with UVITEC Cambridge. Quantitative 
densitometry analysis of proteins was performed using UVBand software (UVITEC 
Cambridge). 
 
13. Stereology 
 
All analyses were carried out on coded slides by investigators blinded to the groups’ 
identity. The occurrence of PK-resistant α-syn immunoreactive deposits, as either LB-
like inclusions (defined as dense, darkly stained intraneuronal cores) or LN-like 
inclusions (defined as dense, darkly stained neurites) in the hippocampal formation, was 
quantified using an unbiased stereological estimation method based on the optical 
fractionator principle [443]. α-syn immunoreactive neurons and processes were counted 
bilaterally in the CA1 subfield of the hippocampus and in the dentate gyrus (i.e. the areas 
in close proximity to the injection site), using about 10 sections per rat located between 
2.1 and 4.5 mm caudal to bregma. The same analyses were also carried out to 
quantitatively estimate the presence of α-syn immunoreactive deposits in projection areas 
outside the injection site, namely the EC. The sampling system consisted of an Olympus 
BH2 microscope (fitted with an X-Y motorized stage and a microcator to measure 
distances in the Z-axis) interfaced with a color video camera (Sony) and a personal 
computer. The CAST GRID® software (Olympus Denmark A/S, Albertslund, Denmark) 
was used to delineate the hippocampus area at 4x magnification, as well as to generate 
unbiased counting frames which were moved randomly and systematically until the entire 
delineated area was sampled. Using a 100x oil objective, unambiguously positive 
aggregates were identified and counted. For each animal, estimates of the total numbers 
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of neuronal and neuritic aggregates in the hippocampus and EC were obtained according 
to the optical fractionator formula and then plotted as mean ± SEM for each time-point 
analyzed. Accuracy of the stereological procedure was evaluated following [444], and 
values < 0.1 were considered acceptable.  
 
14. RNA extraction and Real Time-quantitative PCR (RT-qPCR) analysis 
 
Total RNA was isolated from about 300 mg of prefrontal cortex from frozen postmortem 
rat brain tissue. RNA processing and qPCR experiment were the same as reported 
previously [445] and the primers sequences were as follows:  For Actb Forward 
CTGTGTGGATTGGTGGCTCT reverse CAGCTCAGTAACAGTCCGCC; for SNCA 
Forward TGTCAAGAAGGACCAGATGGG  reverse TAGTCTTGGTAGCCTTCCTCT 
and  for Prnp forward  CGGTACCAGTCCGGTTTAGG reverse 
GCTTTTTGCAGAGGCCAACA. Differential gene expression of SNCA and PrnP was 
normalized to Actb expression. The relative expression ratio was calculated using the 
ΔΔCT method[446].  
 
15. Statistical analysis 
 
Data fulfilled the criteria for normal distribution and were therefore analyzed using 
parametric tests for all statistical comparisons. Group differences in behavioral 
performance as well as in the numbers of immunostained profiles or α-syn expression 
levels were evaluated by either repeated or one-way analysis of variance (ANOVA), as 
appropriate, followed by Fisher’s Protected Least Significant Difference (PLSD) post-hoc 
test. All data are presented as mean ± SEM, and differences were considered significant 
at p < 0.05.  
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                                                                                                                                 CHAPTER IV 
           RESULTS 
 
1. Behavioral analyses 
 
All animals, regardless of their treatment, increased in body weight and exhibited fairly 
normal sensory-motor functioning when evaluated in the three-day cued test at 3 months 
post-injection (Fig. 4.1). In fact, the groups improved their performance over time 
(repeated measures ANOVA, effect of day on latency, F2,66 = 51.79; on distance, F2,66 
= 42.44; both p < 0.001) and did not differ from each other (main group effect on latency 
F2,33 = 0.11; on distance F2.33 = 0.13; group x day on latency F4,66 = 0.23; on distance 
F4,66 = 0.23; all n.s.). Moreover, swim speed, monitored as a measure of motor ability 
throughout the execution of the various tasks, averaged 0.2-0.3 m/sec and did not differ 
between groups at any time-point, indicating that the treatments did not produce any 
sensory or motor impairments that would affect navigation search in the pool. As 
revealed by statistics, rats with sham injections did not differ from the intact animals on 
any of the behavioral or morphological parameters analyzed. These animals were 
therefore combined into a single Control group (n = 18) for all illustrations. 
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Figure 4.1 Groups performance during the cued version of the Morris water maze test at 3 months 
post injection. In this task, the visually cued escape platform was moved to a different quadrant on each of 
the four daily trials, and average escape latencies (A) and swim distances (B) were recorded. Each point 
represents the mean value ±SEM for the block of four trials administered each day, over the three training 
days. 
 
2. Morris water maze test 
 
Mean latencies and swim distances required to find the hidden platform in the reference 
memory version of the Morris water maze task administered at 3 months post-injection, 
are shown in Fig. 4.2 A, B. All animals rapidly learned to locate the platform and 
improved significantly over the five testing days (repeated measures ANOVA, effect of 
day on latency, F4,132 = 43.93; on distance, F4,132 = 40.58; both p < 0.001), reaching an 
asymptotic performance already on day three. The animals appeared to learn the tasks at 
similar rates, and no significant differences were observed between the groups (main 
group effect on latency F2,33 = 0.47; on distance F2.33 = 0.60; group per day on latency, 
F8,132 = 0.16; on distance F8,132 = 0.18; all n.s.). During the spatial probe trial, on the 
last day of testing, when the platform was removed for a 60 s free swim (Fig. 4.2 C-E), 
all animals swam primarily in the training (NE) quadrant, where the platform was 
originally located (repeated measures ANOVA, effect of quadrant on swim distance, 
F3,99 = 36.73; on annulus crossings, F3,99 = 74.06, both p < 0.001), with equal 
efficiency (main group effect on distance F2,33 = 0.67; on annulus crossings, F2,33 = 
1.87; group per quadrant interaction for distance, F6,99 = 1.35; for annulus crossings 
F6,99 = 1.39, all n.s.). In addition, no group difference was observed in the total number 
of collisions with the annuli or swim speed (one-way ANOVA, main group effect, 
respectively, F2.33 = 1.87 and F2,33 = 0.01; both n.s.), indicating an equally active and 
spatially focused search behavior in all animals. 
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Figure 4.2 Performance during the Water maze reference memory test at 3 months post injection. 
Average latency (A) and swim distance (B) required to locate the submerged platform during the 
acquisition phase of the spatial navigation task. Each sample point represents the mean value ±SEM for the 
block of four trials on each of the five consecutive days of testing. Lower diagrams illustrate the mean 
relative distance swum (C) and the average number of annulus crossings (D) in each quadrant during the 
spatial probe trial, once the escape platform was removed from the NE (training) quadrant. In E, the actual 
swim paths taken by representative animals from the different groups are shown. All groups exhibited an 
equally efficient performance, indicating that the α-syn injection had no effects on this task. NE, North-
East; NW, North-West; SE, South-East; SW, South-West 
 
At about 12 months post-surgery, upon conclusion of the last 2-trial RAWM session (see 
below), the animals were tested again in the Morris water maze task in order to evaluate 
possible delayed effects of the injected α-syn PFFs, as a result of their progressive 
spreading. Only the data referring to the spatial probe trial will be reported here (Fig. 4.3 
A-C). Consistent with the observations at the 3 months’ time-point, the α-syn treatment 
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produced no long-term impairments in reference memory abilities. In fact, all tested 
animals exhibited an equally efficient and focused search behavior in the spatial probe 
trial (repeated measures ANOVA effect of quadrant on swim distance, F3.39 = 9.31; on 
annulus crossings F3.39 = 19.49; both p < 0.001), with no obvious group differences 
(main group effect on distance, F2,13 = 1.29; on annulus crossings, F2,13 = 2.00; group x 
quadrant interaction for distance, F6,39 = 1.25; for annulus crossings F6,39 = 1.76, all 
n.s.). This applied also to the total number of crossings or swim speed. 
 
 
 
Figure 4.3 Performance during the spatial probe trial of the separate 3-d Morris water maze test 
administered just before killing, at 12 months post injection. The mean relative distance swum (A), the 
average number of annulus crossings (B), and the actual swim paths taken by representative animals from 
the different groups (C) are illustrated. Consistent with the observations at the 3 months’ time point, no 
long-term impairments in reference memory abilities were produced by the α-syn treatment. 
 
3. Radial arm water maze test 
 
Group performances in the RAWM task, when first administered at 3 months post-
injection, are shown in Fig. 4.4 A-E. In this design, the platform position was moved to a 
new arm daily, thus the animals had to re-learn its position within the five trials of each 
testing day by developing a new search strategy. As expected, all animals required a 
longer latency and made a higher number of arm selection errors (i.e., entering an arm not 
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containing the platform or an arm which had already been visited) during the first trial of 
each day, but they improved over the five trials (repeated measures ANOVA, effect of 
trial on latency, F4,132 = 57.76; on errors, F4,132 = 45.69; both p < 0.001). At the 3 
months’ time-point, the ability to progressively reduce the latency and errors required to 
locate the hidden platform was similar for all animals, and no group difference was 
detected (main group effect on latency, F2,33 = 0.19; on errors F2,33 = 0.45; group per 
trial interaction on latency F8,132 = 0.67; on errors, F8,132 = 0.55; all n.s.). Inspection of 
latency and errors savings, calculated as percentage improvement between trials 1 and 2, 
confirmed a ~ 40-48% reduction of latency and entry errors, with no obvious group 
difference (one-way ANOVA with Fisher’s PLSD post-hoc test, all n.s.). The swim paths 
obtained on the fifth day of training from representative animals are shown in Fig. 4.4 E. 
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Figure 4.4. Working memory performance in the RAWM task, at 3 months post injection, 
illustrating latency (A) and number of entry errors (B) required by the animals to find the hidden 
platform. Each sample point represents the mean latency and errors ±SEM recorded during each 60-s trial 
over five consecutive testing days. In the lower diagrams, performances are plotted as percent savings 
between trials 1 and 2 for latency (C) and errors (D). In E, the actual swim paths taken by representative 
animals from the different groups are illustrated. All groups exhibited an equally efficient performance, 
indicating no clear-cut effects of α-syn on working memory at this time point. 
 
4. Two-trials radial arm water maze test 
 
Starting from 5 months and up to about 12 months post-injection, the animals were tested 
using a modified version of the RAWM task, with two daily trials administered over two 
consecutive days. The testing was then organized, with intervening sacrifices of 
randomly selected subjects from the various groups at different time-points post-
injection, so as to have three main blocks of six sessions administered weekly or every 
two weeks, as outlined above. By such design, latency and error savings, calculated as 
percentage improvement from trial 1 to 2, provided a measure of working memory 
performance and its possible changes over time (Fig. 4.5 A-C). During the first two 
blocks (weekly sessions 1-6 and 7-12 starting at 5 and 7 months post-injection, 
respectively) animals in the groups were equally efficient in reducing both escape latency 
and number of errors across trials, and no significant group difference was detected (one-
way ANOVA, all p > 0.05, n.s.). By contrast, in the third block of sessions (administered 
every two weeks starting from the 9th month post-injection), α-syn-treated animals were 
seen to progressively worsen their performance. In fact, the calculated percent 
improvements in both latency and errors appeared significantly lower than those 
exhibited by the Sham-injected and Intact groups already on session 15 (one-way 
ANOVA, p < 0.01 or p < 0.05 for both measures), and remained unmodified up to 
session 18, when the training criterion (i.e. significant group differences in at least three 
consecutive sessions) was considered fulfilled and the 2-trial RAWM testing was 
interrupted (actual swim paths from representative animals are illustrated in Fig. 4.5 C). 
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Figure 4.5 Working memory performance during the two trials RAWM, from 5 to 12 months post 
injection. Data represent the percentage rate of improvement between the first and the second trial 
(savings) in latency (A) and errors (B). All groups exhibited an equally efficient working memory during 
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the first two blocks of weekly sessions, administered at 5 and 7 months post injection, respectively; 
however, α-syn-treated animals progressively worsened their performance and appeared significantly 
impaired during the third block of sessions, administered every two weeks. In C, the actual swim paths 
taken by representative animals from the different groups in the various blocks are illustrated. Asterisks 
indicate significant difference from control at p<0.01.  
 
5. Morphological analyses 
  
Consistent with previous observations [403], sonication of α-syn fibrils resulted in the 
formation of relatively small and homogeneous fibrillary assemblies, as revealed by AFM 
(Fig. 4.6). By contrast, no such pattern was exhibited by the non-preaggregated protein 
(not shown). 
 
                          
 
Figure 4.6 Atomic force microscopy image of sonicated of α-syn fibrils. Image was acquired with 
tapping mode in air, at room temperature working in dynamic mode by the use of a commercially available 
microscope (Solver Pro AFM from NT-MDT – NT-MDT Co. – Moscow – Russia) endowed with a closed-
loop scanner[403].  
 
The bilateral injection of synthetic mouse α-syn fibrils into the hippocampus resulted in 
the occurrence and progressive accumulation of α-syn-immunoreactive aggregates in 
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various hippocampal subfields (e.g. Dentate Gyrus, DG, Fig. 4.7A-F and Cornu 
Ammonis, CA1, Fig. 4.7G-L’) whereas no such α-syn aggregates were found in the brain 
of sham-injected or intact animals (compare e.g. with corresponding regions in Control 
animals, Fig. 4.7A–F’). In general, the strong PK-resistant α-syn immunoreactivity 
occurred as both LB-like and LN-like deposits (Fig. 4.7M-N) and was detected not only 
in the proximity of the injection site but also in distinct anatomically related regions, with 
a morphology and distribution pattern that varied in a time-dependent fashion. Thus, as 
estimated by stereology, relatively few α-syn-immunoreactive LB-like inclusions were 
found in the hippocampal CA1 and dentate gyrus subfields at about 7 months post-
injection, their numbers showing a significant 2.2- and 5.8-fold increase at 9 and 12 
months, respectively (one-way ANOVA with Fisher’s PLSD post-hoc test, P < 0.05; Fig. 
4.7O). Conversely, the number of LN-like deposits in the same regions was slightly 
higher at 7 months post-injection and exhibited a non-significant reduction at 9 and 12 
months (Fig. 4.7P).  
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Figure 4.7. Representative micrographs illustrating, on the coronal plane, the negligible expression of 
PK-resistant a-syn immunoreactivity at 7, 9 and 12-months post-injection in the hippocampal DG 
(A–C, insets shown in A’–C’) and in the CA1 region (D–F, insets shown in D’–F’) of control rats. 
Progressive aggregation of a-syn after injection of recombinant mouse a-syn fibrils into the hippocampus. 
Compared with control, a strong PK-resistant a-syn immunoreactivity was found at seven, nine-, and 12-
months post-injection in the DG (G–I, insets shown in G’–I’) and in the CA1 region (J–L, insets shown in 
J’–L’) of injected rats. PK-resistant a-syn aggregates occurred as darkly stained LB-like (arrows) and LN-
like deposits (arrowheads) and are shown at higher magnification in M, N. Box-whiskers plots illustrate the 
stereologically estimated numbers at different time points 6 min to max value of LB-like (O) and LN-like 
(P) inclusions in the hippocampus of rats injected with the a-syn fibrils. Scale bars: 500 µm (in A, D, G, J 
for A–C, D–F, G–I, J–L), 100 µm (in A’, D’, G’, J’ for A’–C’, D’–F’, G’–I’, J’–L’), and 5 µm (M, N). 
Asterisk in O indicates significant time dependent changes at p<0.05. 
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LB-like and LN-like inclusions in the EC were virtually undetectable or very sparse at 7 
months post-injection but they became clearly visible already at 9 months (Fig. 4.8A-F’; 
compare with corresponding regions in Control animals, Fig. 4.8A–C’), and their 
numbers increased significantly over time (one-way ANOVA with Fisher’s PLSD post-
hoc test, both p < 0.05; Fig. 4.8G-H). 
                    
                              
 
Figure 4.8. Representative micrographs illustrating, on the coronal plane, the negligible expression of 
PK-resistant a-syn immunoreactivity at 7, 9, and 12 months post injection in the entorhinal cortex 
(A–C, insets shown in A’–C’) of control rats. Progressive a-syn aggregation after injection of 
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recombinant mouse a-syn fibrils into the hippocampus. A strong PK-resistant a-syn immunoreactivity 
occurring as both LB-like (arrows) and LN-like (arrowheads) deposits was also found at 7, 9, and 12 
months post injection in the entorhinal cortex (D–F, insets shown in D’–F’) of injected rats. Box-whiskers 
plots illustrate the stereologically estimated numbers at different time points 6 min to max value of LB-like 
(G) and LN-like (H) inclusions in the entorhinal cortex of the injected rats. Scale bar: 500 µm (in A, D for 
A–C, D–F) and 100 µm (in A’, D’ for A’–C’, D’–F’). Asterisks in G, H indicate significant time-dependent 
changes at p<0.05.  
 
By contrast, only at 12 months were α-syn immunoreactive LB-like and LN-like 
inclusions found in other projection areas, such as the vertical limb of the diagonal band, 
and the anterior and posterior piriform cortices, being barely detectable at earlier time-
points (Fig. 4. 9A-F’ compare with corresponding regions in Control animals Fig. 4.9A–
C’).  
In either form, occurrence of α-syn immunoreactivity in the hippocampus or entorhinal 
cortex did not appear to result in disrupted morphology or architecture of local neuronal 
populations (Fig. 4.9 G–L) 
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Figure 4.9. Representative micrographs illustrating, on the coronal plane, the negligible expression of 
PK-resistant α-syn immunoreactivity at 12 months post injection in the vertical limb of the DBB 
(vDBB; A, inset shown in A’), and the anterior and posterior piriform cortices (aPC and pPC; B, C, 
respectively, insets shown in B’, C’). Spreading of a-syn aggregates. A strong PK-resistant α-syn 
immunoreactivity was also found at 12 months postinjection in the vDBB (D, inset shown in D’, arrow) 
and the anterior and posterior piriform cortices (aPC and pPC, E, F, insets shown in E’, F’; arrows and 
arrowheads indicate LB-like and LN-like inclusions, respectively). Scale bar: 100 µm (in A, D, for A–C, 
D–F) and 50 µm (D for D–F). Cresyl violet staining of the entorhinal cortex (ENT CTX), hippocampus 
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(HPC), and piriform cortex (PC) of control (G, H, I, respectively) and α-syn-injected animals (J, K, L, 
respectively). Scale bar: 100 µm (in G for G–L). 
 
Moreover, separate morphometric analyses, carried out to assess the possible toxic effects 
of α-syn overexpression, revealed that at no time-point post-injection was any obvious 
loss of dopaminergic, cholinergic or noradrenergic neurons detected in the Substantia 
Nigra (SN), the Ventral Tegmental Area (VTA), Medial Septum/Diagonal Band of Broca 
(MS/DBB) or Locus Coeruleus (LC), respectively. Thus, occurrence and distribution of 
tyrosine hydroxylase (TH)-, choline acetyltransferase (ChAT)- or dopamine-beta-
hydroxylase (DBH)-immunoreactive neurons did not differ between α-syn-injected and 
control animals in any of the analysed regions (data not shown)  
 
Consistent with the above observations of a time-dependent increase of PK-resistant α-
syn aggregates within the hippocampus, immunofluorescence confirmed the progressive, 
increase of Ser129-phosphorylated α-syn in the hippocampus of injected rats (Fig. 4.10A-
C), whereas no such immunoreactivity was detected in controls (not shown). Subsequent 
analyses of fluorescence intensity and localization profile in Ser129-phosphorylated a-
syn P-α-syn-GFAP double immunostained specimens at 7, 9 and 12 months post-
injection revealed virtually no co-localization of these markers. In fact, close inspection 
of the expression profile plots of P-α-syn and GFAP immunoreactivities showed very 
poor or no juxtaposition between the respective peaks, thus ruling out a glial occurrence 
of Ser129-phosphorylated α-syn as a result of intracerebral α-syn fibril treatment at any 
time-point post-injection (Fig. 4.10A'-C' and A"-C"). 
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Figure 4.10. Confocal microscopy images illustrating the progressive increase of hippocampal 
Ser129-phosphorylated α-syn (A–C) and the lack of co-localization with GFAP at seven, nine, and 12 
months after the injection of recombinant mouse α-syn fibrils into the hippocampus. In the lower 
diagrams, analysis of fluorescence intensity (A’–C’) and surface plot profiles (A”–C”) of confocal images 
in A–C indicate very poor or no glial occurrence of the Ser129-phosphorylated a-syn. Scale bars: 50 µm 
(A–C). Long-term effects of α-syn fibril injection 
 
6. Western blot analyses  
 
At 12 months post injection, Western blot analyses were carried out on tissue 
homogenates from the hippocampus and the prefrontal and frontoparietal cortices of 
control and α-syn-injected rats. Due to technical reasons (accidental loss of the 
homogenate samples), western blot analyses on the EC could not be carried out and will 
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not be reported here. The analyses were designed to obtain estimates of the relative levels 
of non-phosphorylated and Ser129-phosphorylated α-syn. The procedure (as described 
above) enabled the detection of a ∼15 kDa band, that represents the non-phosphorylated 
α-syn [274], a ∼80 kDa which correspond to Ser129-phosphorylated α-syn (Fig. 4.11 A-
C) and a ∼35 kDa for PrPc (Fig. 4.11D-F). Densitometric analysis of the bands after 
normalization against β-actin revealed a significant 50% increase of the Ser129-
phosphorylated α-syn level only in the hippocampus of α-syn treated rats compared to 
controls (p < 0.01; Fig.4.11A'). By contrast, no group differences in Ser129-
phosphorylated α-syn expression were detected in prefrontal and frontoparietal cortices 
(Fig.4.11B'-C'), nor did the α-syn treatment affect the expression of non-phosphorylated 
α-syn in any of the analyzed regions. Likewise, the expression levels of PrPc in these 
regions was similar in the two groups (Fig. 4.11D'-F'). 
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Figure 4.11. Long-term effects of intrahippocampal a-syn fibril injection on regional tissue levels of 
Ser129-phosphorylated a-syn (Pa-syn), non-phosphorylated a-syn (non-P-a-syn), and PrPc. Representative 
Western blotting bands and densitometric analyses illustrate the expression levels of the various proteins in 
the hippocampus (A, A’, D, D’), fronto-parietal cortex (B, B’, E, E’), and prefrontal cortex (C, C’, F, F’) of 
rats injected with a-syn fibrils and controls at 12 months post injection. The values are shown as a 
percentage of P-a-syn, non-P-a-syn forms, or PrPc relative to b -actin, this latter being the loading control. 
Data are represented as mean ± SEM. Asterisk in A’ indicates significant difference from control at p<0.05. 
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7. RT-qPCR analysis   
 
To evaluate the differential gene expression of SCNA and PrnP, RT-qPCR analysis was 
performed on tissue homogenates from prefrontal cortex of control and α-syn-injected 
rats at 12 months post injection. There was no significantly increased expression level of 
SCNA mRNA and PrnP mRNA in α-syn injected rats compared to control (Fig. 4.12). 
 
           
 
Figure 4.12 Quantification of the mRNA expression levels of SNCA and PrnP in prefrontal cortex (A) and 
in the hippocampus (B) of rats injected with a-syn fibrils and controls at 12 months postinjection. Data are 
represented as mean fold change over control ±SEM.  
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                                                                                                                         CHAPTERV 
 
DISCUSSION AND CONCLUSION  
 
The aim of this study was to evaluate the anatomical, neurochemical, molecular and 
behavioral effects of recombinant mouse α-syn PFFs following intrahippocampal 
injection in the adult rat. The injections resulted in the time-dependent occurrence of PK-
resistant α-syn aggregates within the hippocampus suggesting that neurons in this region 
may be particularly susceptible to transmitted α-syn pathology. Moreover, in keeping 
with previous findings following intrastriatal/intracortical administration in mice [389] 
the present data lend support to the notion that pathological α-syn can spread over 
considerable distances to several central regions, which is also consistent with the prion 
like hypothesis. In fact, PK-resistant α-syn aggregates were also found in anatomically 
related areas, such as the EC, the vDBB and the piriform cortices, which, interestingly, 
was associated to the onset of specific deficits in spatial working memory, i.e. the kind of 
memory function that is commonly impaired in PD patients [447]. 
Thus, at 7 months post injection, α-syn immunoreactivity in the hippocampus was mainly 
associated to neuritic processes and relatively few intracellular inclusions were detected. 
This observation is consistent with previously suggested explanation according to which 
the onset of α-syn accumulation in axons may be due to the physiological high-level 
content of endogenous α-syn within the presynaptic terminals [283, 448]. In addition, the 
pathological staging of PD confirmed that Lewy neurite formation precedes Lewy body 
formation[22]. In the hippocampus, the numbers of Lewy-like neuritic inclusions did not 
vary significantly over time, whereas in the EC the estimated numbers of α-syn 
immunoreactive neurites were seen to increase between 7 and 9 months but remained 
virtually unchanged thereafter. In both regions, the immunoreactive material appeared to 
progressively invade somata and already at 9 months, the number of neuronal profiles 
with dense perinuclear LB-like inclusions was seen significantly increased. Interestingly, 
inclusions of α-syn immunoreactive material in both the hippocampus and EC exhibited 
the most dramatic increases (by about 6- and 10-fold, respectively) at 12 months post-
injection. The time-course and dynamics of intracellular α-syn occurrence, with more 
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dramatic increases detected between 9- and 12-months post-injection, i.e. concurrently to 
the onset of cognitive impairments, points to a precise time window, relatively long after 
its injection into the brain parenchyma, when α-syn is capable to massively accumulate 
inside neurons and efficiently interfere with their functioning. The present findings 
appear consistent with previous observations of remarkably slow progression of α-syn 
pathology in PD patients [449, 450], thus confirming the feasibility of the α-syn PFF 
infusion paradigm as a tool for modelling aspects of cognitive loss in PD. In fact, a 
significant trend towards a worsened performance in the RAWM task was seen from 9 
months post injection, to become dramatically evident at 12 months. Interestingly, at no 
time point post-injection was any motor disturbance detected in the injected animals, nor 
was α-syn found within regions rich in dopamine neurons and fibers, such as the SN, the 
VTA or the Striatum. In addition, no obvious loss in dopaminergic, noradrenergic or 
cholinergic immunoreactivity was detected in α-syn-injected animals compared to 
controls, thus the behavioural impairments seen in the α-syn injected animals appear to 
be determined by the long-term persisting α-syn neuropathology in the affected neurons 
rather than by neurodegeneration, which is consistent with the observations by Hall and 
colleagues [431]. These observations are also in keeping with the findings of a recent in 
vitro study [451] showing that treatment of excitatory hippocampal neurons with α-syn 
fibrils after 7 days induced neuronal dysfunctions before the occurrence of neuronal death 
when α-syn inclusions primarily localize to axons. Indeed, Froula and colleagues found 
that exposure of neurons to α-syn fibrils caused a Paradoxically, reduced postsynaptic 
spine density which was accompanied by increased frequency of miniature excitatory 
postsynaptic currents (EPSCs) and presynaptic docked vesicles, suggesting enhanced 
presynaptic function. In addition, neurons exposed to α-syn fibrils, showed reduced 
frequency and amplitudes of spontaneous Ca2+ transients confirming the detrimental 
effect of α-syn fibrils on synaptic activity as previously described in others studies[452, 
453]. However, Action-potential dependent activity was unchanged, suggesting 
compensatory mechanisms responding to synaptic defects at the level of synapse. In fact, 
Froula and colleagues suggested that the transformation of normal α-syn into pathologic 
aggregates at the presynaptic terminal increased presynaptic activity with a reduction of 
dendritic spines which can be considered as a homeostatic response to the increase 
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presynaptic activity, thus causing no changes in spontaneous synaptic events. 
Furthermore, Wu and coworkers after using a whole cell patch clamp technique to 
investigate synaptic activity modulation after exposure to α-syn FFs at the single-cell 
level reported decreased synaptic activity within 10 min following the direct 
administration of PFFs to the neuron before neuronal death occurrence at 7 days post 
administration[452]. All together these data, in accordance with ours, suggested that 
neuronal α-syn pathology could induced negative changes in synaptic function which 
could lead to cognitive impairment before the occurrence of neuronal death. Moreover, 
the compensatory mechanisms (found by Froula and colleagues) responding to synaptic 
defects induced by α-syn fibrils could explain the long-time window before the onset of 
memory impairments observed in the present study.  
Considering the occurrence of α-syn immunoreactivity in the EC and, at 12 months post-
injection, in the vDBB and the piriform cortices, i.e. all regions involved in memory 
functions and the time-course and regional pattern of α-syn accumulation, the present 
data therefore suggest that hippocampal Lewy pathology must spread beyond its initial 
site, towards cognitively-relevant areas, to induce measurable memory dysfunctions. This 
is consistent with the model proposed by Adamowicz et al. [435] according to which 
learning, and memory impairment become apparent once Lewy pathology concurrently 
affects CA1 and EC.  
The mechanism underlying the hippocampal Lewy pathology induced memory 
impairment needs to be further elucidated. However, it has been reported that deficits in 
learning and memory observed in α-syn transgenic mice are accompanied by alterations 
in post-synaptic densities [454] or reduction in presynaptic vesicle-associated proteins 
such as synaptophysin [433], suggesting that the toxicity of α-syn may be mediated by 
disturbances in synaptic transmission and plasticity [455, 456]. α-syn FFs have been also 
shown to hampers synapse formation, disrupt spine dynamics and morphology, all events 
known to be involved in learning and memory. In particular, the reduced spine density 
induced by α-synuclein pathology may be a pathophysiological phenotype contributing to 
dementia [457, 458]. Indeed, it has been demonstrated that increasing in spine density of 
CA1, CA3 and dentate gyrus neurons of the rat hippocampus is positively proportional to 
RAWM performance (thus reduced working memory errors and latency) in trained 
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rats[459]. Thus, α-syn PFFs induced disruption of spine dynamics and morphology may 
underly the working memory impairment observed in α-syn PFFs injected rats in this 
study. However, further analyses assessing spine dynamics and morphology in relevant 
areas and at different time points after α-syn PFFs injection are needed.  
In a recent investigation, Aulić and coworkers([403] found that the PrPc binds α-syn 
amyloids to get access into the cell and accumulate into cytoplasm, thereby facilitating 
the cell-to-cell spreading of the pathology. Likewise, it has been reported that α-syn 
oligomeric species interact with PrPc through mGluR5, activating SFK kinases and, 
subsequently, NMDAR2B to induce neuronal dysfunction and cognitive deficits in Thy1- 
α-syn mice and also that the toxic effects induced by α-syn oligomers may be prevented 
using antibody-mediated inactivation of PrPc [404]. Taken together these studies have 
identified previously unknown components of the signaling cascade triggered by α-syn, 
therefore suggesting that PrPc signaling might be involved in the pathogenesis of 
synucleinopathies and may be used as a potential therapeutic target to prevent or slow 
down the progression of synucleinopathies. Surprisingly, in the present study, the 
immunoprecipitation approach provided no evidence of any complexes formed in the 
hippocampus between PrPc (data not shown) with either non-phosphorylated or 
phosphorylated α-syn at 12 months post-injection. Considering that the α-syn-PrPc 
interactions reported by both Aulic et al. (2017) and Ferreira et al. (2018) are detected in 
5–8-month-old animals, it is possible to assume the existence of specific stages during 
which the interaction of these proteins may actually take place, leading to a massive α-
syn spreading, to become less pronounced at later time-points, once the spreading is well 
ongoing. This may be of potential interest, as it may highlight a valuable window of 
therapeutic opportunity, whose full understanding, again, requires further investigation.   
PrPc level in the hippocampus, prefrontal and fronto-parietal cortices of α-syn-injected 
rats was similar to controls at 12 months post-injection, as well as PrPc mRNA and α-syn 
mRNA levels in the prefrontal cortex which is consistent with previous observations 
[403]. This appear to confirm that the level of PrPc and α-syn transcripts were not altered 
after fibrils injection and that the observed increase of pathological α-syn is likely to 
occur at protein accordingly to the already described prion like hypothesis. 
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Increased level of phosphorylated α-syn at serine 129 represents one of the hallmarks of 
PD. In fact, approximately 90% of α-syn deposited in LBs is phosphorylated at serine 
129 (Ser129) while only 4% or less of the total α-syn is phosphorylated at this residue in 
brains from individuals without PD [274, 460]. Nevertheless, the significance of 
phosphorylation in the biology and pathophysiology of the protein is still controversial 
and both in vitro and in vivo studies, examining phosphorylation of α-syn at different 
sites, have reported conflicting results, showing either promotion [323], inhibition [461] 
or no effect [462] on inclusion formation. However, to assess the role, if any, of the 
phosphorylation of α-syn fibrils in the seeding and pathological accumulation of α-syn, 
Karampetsou and colleagues found that phosphorylated α-syn -PFFs are more efficiently 
uptaken by neurons after injection in wild type mice, leading to increased seeding and 
accumulation of the endogenous α-syn. This suggests that phosphorylation adds 
“aggregation” capacity to the α-syn assemblies and as such may regulate the onset of 
neuronal dysfunction[322]. Similarly, we found after injection of non-phosphorylated 
recombinant mouse α-syn fibrils in rats, a time–dependent increase of Ser-129 
phosphorylated α-syn into the hippocampus with the overt manifestation of cognitive 
deficits. Our data, therefore, not only provide a further proof of the importance of 
phosphorylation in the pathogenesis of disease but also allow the validation of our 
experimental model.  
In the present study we used the α-syn PFFs as a model to examine the long-term 
behavioral effects induced by misfolded α-syn within the hippocampus.  However, we 
did not address the eventual neuroinflammation that could result from α-syn PFFs 
injection. Previous studies using α-syn PFFs revealed an increased microglial activation 
followed by the release of proinflammatory mediators which may be the cause rather than 
the consequence of neurodegeneration[414]. Indeed, intranigral injection of α-syn PFFs 
in rats induced the major histocompatibility complex (MHC) II response 24 hours post 
injection, which persisted over time, and was accompanied by CD163-positive cells, 
revealing the infiltration of scavenger macrophages from the periphery. Interestingly, SN 
was invaded by a high number of of CD45High/Cb11b macrophages and CD4+ T cells at 
2 months post injection even though no changes in the number of microglia were evident 
suggesting changes in microglial activation instead of an increase in proliferation. 
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Furthermore, the lack of apparent nigrostriatal degeneration led to the suggestion 
according to which, the cause of degeneration may be due to the recruitment of peripheral 
immune cells expressing proinflammatory phenotypes triggered by MHC II 
activation[463]. Similar results were found in another study after intrastriatal injection of 
α-syn PFFs in rats suggesting that the activation of inflammatory components, like MHC 
II, represent a primary defense mechanism upon the presence of inclusions in hope of 
aggregate burden reduction[464]. Indeed, Olanow and colleagues showed that microglial 
inflammatory responses precede the propagation of Lewy body pathology in human fetal 
tissues grafted into patient brains, which indicates that in humans, immune responses are 
early events rather than late events in association with aggregate propagation[465]. 
However, these early immune responses might contribute to neuronal vulnerability and 
lead to degeneration[464]. Thus, in light of the previous studies, the apparent lack of 
neurodegeneration observed 12 months after α-syn PFFs injection in the present study 
may indicate a lack of neuroinflammation which however requires further investigation 
given the fact that differences in the inflammatory profile were shown to depend on the 
site of injection, type of seed, and time point of pathology assessment[322, 412, 463, 
466]. 
 
In conclusion, our study shows that bilateral injection of recombinant mouse α-syn PFFs 
into the hippocampus of rat was sufficient to trigger α-syn pathology within the 
hippocampus and spread it in EC, vDBB and piriform cortex leading to working memory 
impairment. Although the mechanism behind α-syn-mediated working memory 
impairment has to be further elucidated, the present study provides an additional proof 
that α-syn may be one the main neuronal substrates for cognitive impairment in 
synucleinopathies. 
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